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8ABSTRACT
Pioglitazone is a thiazolidinedione compound used in the treatment of type 2 diabetes. 
It has been reported to be metabolised by multiple cytochrome P450 (CYP) enzymes, 
including CYP2C8, CYP2C9 and CYP3A4 in vitro. Th e aims of this work were to 
identify the CYP enzymes mainly responsible for the elimination of pioglitazone in 
order to evaluate its potential for in vivo drug interactions, and to investigate the eff ects 
of CYP2C8- and CYP3A4-inhibiting drugs (gemfi brozil, montelukast, zafi rlukast 
and itraconazole) on the pharmacokinetics of pioglitazone in healthy volunteers. In 
addition, the eff ect of induction of CYP enzymes on the pharmacokinetics of 
pioglitazone in healthy volunteers was investigated, with rifampicin as a model 
inducer. Finally, the eff ect of pioglitazone on CYP2C8 and CYP3A enzyme activity 
was examined in healthy volunteers using repaglinide as a model substrate.
Study I was conducted in vitro using pooled human liver microsomes (HLM) and 
human recombinant CYP isoforms. Studies II to V were randomised, placebo-
controlled cross-over studies with 2-4 phases each. A total of 10-12 healthy volunteers 
participated in each study. Pretreatment with clinically relevant doses with the 
inhibitor or inducer was followed by a single dose of pioglitazone or repaglinide, 
whereaft er blood and urine samples were collected for the determination of drug 
concentrations.
In vitro, the elimination of pioglitazone (1 µM) by HLM was markedly inhibited, in 
particular by CYP2C8 inhibitors, but also by CYP3A4 inhibitors. Of the recombinant 
CYP isoforms, CYP2C8 metabolised pioglitazone markedly, and CYP3A4 also had 
a signifi cant eff ect. All of the tested CYP2C8 inhibitors (montelukast, zafi rlukast, 
trimethoprim and gemfi brozil) concentration-dependently inhibited pioglitazone 
metabolism in HLM. In humans, gemfi brozil raised the area under the plasma 
concentration-time curve (AUC) of pioglitazone 3.2-fold (P < 0.001) and prolonged 
its elimination half-life (t½) from 8.3 to 22.7 hours (P < 0.001), but had no signifi cant 
eff ect on its peak concentration (Cmax) compared with placebo. Gemfi brozil also 
increased the excretion of pioglitazone into urine and reduced the ratios of the 
active metabolites M-IV and M-III to pioglitazone in plasma and urine. Itraconazole 
had no signifi cant eff ect on the pharmacokinetics of pioglitazone and did not alter 
the eff ect of gemfi brozil on pioglitazone pharmacokinetics. Rifampicin decreased 
the AUC of pioglitazone by 54% (P < 0.001) and shortened its dominant t½ from 
4.9 to 2.3 hours (P < 0.001). No signifi cant eff ect on Cmax was observed. Rifampicin 
also decreased the AUC of the metabolites M-IV and M-III, shortened their t½ 
and increased the ratios of the metabolite to pioglitazone in plasma and urine. 
Montelukast and zafi rlukast did not aff ect the pharmacokinetics of pioglitazone. Th e 
pharmacokinetics of repaglinide remained unaff ected by pioglitazone.
ABSTRACT
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9Th ese studies demonstrate the principal role of CYP2C8 in the metabolism of 
pioglitazone in humans. Gemfi brozil, an inhibitor of CYP2C8, increases and 
rifampicin, an inducer of CYP2C8 and other CYP enzymes, decreases the plasma 
concentrations of pioglitazone, which can necessitate blood glucose monitoring and 
adjustment of pioglitazone dosage. Montelukast and zafi rlukast had no eff ects on the 
pharmacokinetics of pioglitazone, indicating that their inhibitory eff ect on CYP2C8 
is negligible in vivo. Pioglitazone did not increase the plasma concentrations of 
repaglinide, indicating that its inhibitory eff ect on CYP2C8 and CYP3A4 is very 
weak in vivo.
ABSTRACT
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INTRODUCTION
Patients with type 2 diabetes oft en use several drugs concurrently (Reunanen et al. 
2000) and are therefore prone to harmful drug-drug interactions. Many clinically 
important drug interactions are related to cytochrome P450 (CYP) enzymes, whose 
activity can be suppressed (inhibition) or enhanced (induction) by diff erent drugs. 
Pioglitazone is a new thiazolidinedione compound used in the treatment of type 2 
diabetes. It is reported to be extensively metabolised by CYP enzymes in the liver 
(Eckland and Danhof 2000).
CYP enzymes are essential in oxidative drug metabolism, being involved in 
approximately 80% of oxidative drug metabolism and accounting for almost 50% of 
the overall elimination of commonly used drugs (Wilkinson 2005). Th e major CYP 
enzymes involved in human drug metabolism are CYP3A4, CYP2D6, CYP2C8, 
CYP2C9, CYP2C19, CYP1A2 and CYP2B6. Th e liver is the main organ responsible 
for CYP-mediated drug metabolism. However, there are signifi cant amounts of CYP 
enzymes in other tissues as well. For example, the enterocytes in the small intestine 
are an important site of metabolism for many drugs. CYP activities can vary markedly 
between individuals due to genetic and environmental factors and some diseases, 
which can lead to major diff erences in drug response and adverse eff ects.
Inhibition of CYP enzymes can lead to increased plasma concentrations of drugs 
metabolised by the same enzymes, thereby enhancing their pharmacological eff ects 
and increasing the likelihood of adverse eff ects. Induction of CYP enzymes can 
reduce the plasma concentrations and eff ects of substrate drugs. Some prodrugs need 
to be metabolically activated by CYP enzymes, and inhibition of their metabolism 
can reduce their eff ects, while induction can either enhance or reduce their eff ects 
and toxicity, depending on the eff ects of induction on the further elimination of the 
active metabolite.
Pioglitazone decreases insulin resistance via its action at the peroxisome proliferator 
activated receptor subtype gamma (PPAR-γ)(Yki-Järvinen 2004). It is not an insulin 
secretagogue and does not therefore cause hypoglycaemia when used alone. Its most 
common clinically important adverse eff ect is fl uid retention, which can lead to or 
exacerbate heart failure and pulmonary oedema (Waugh et al. 2006).
In vitro studies have suggested that pioglitazone is metabolised by multiple CYP 
enzymes, mainly by CYP2C8, CYP2C9 and CYP3A4 (Eckland and Danhof 2000), but 
it seems that the studies on the contribution of diff erent CYP isoforms have not been 
published. Moreover, manufacturer’s information from diff erent sources concerning 
the roles of CYP2C8 and CYP2C9 is discrepant (Actos prescribing information, 
Pharmaca Fennica: Actos). Furthermore, the relative contribution of diff erent CYP 
enzymes in vivo and the eff ects of CYP enzyme induction and CYP2C8 inhibition on 
the metabolism of pioglitazone in humans are unknown. Pioglitazone is reported to 
INTRODUCTION
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inhibit both CYP2C8 (Sahi et al. 2003, Walsky et al. 2005a) and CYP3A4 (Sahi et al. 
2003) enzymes in vitro, but its inhibitory eff ect on CYP2C8 activity in vivo has not 
been investigated. 
Th e purpose of this work was to identify the CYP enzymes mainly responsible for the 
elimination of pioglitazone and to investigate the eff ects of the in vivo CYP2C8 inhibitor 
gemfi brozil, the CYP3A4 inhibitor itraconazole, the in vitro CYP2C8 inhibitors 
montelukast and zafi rlukast and the CYP inducer rifampicin on the pharmacokinetics 
of pioglitazone in healthy volunteers. In addition, this work investigated the eff ect of 
pioglitazone on the pharmacokinetics of repaglinide in healthy volunteers in order to 
characterise its potential to inhibit CYP2C8 and CYP3A enzyme activity in humans.
INTRODUCTION
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REVIEW OF THE LITERATURE
1. Pharmacokinetics and drug interactions
Pharmacokinetics explores the time course of a drug and its metabolites in the 
body (Tozer and Rowland 2006). Pharmacokinetics is oft en divided into absorption 
and disposition. Absorption describes the movement of a drug from the site of 
administration to the circulatory system. Orally administered drugs are absorbed 
from the gastrointestinal tract and carried via the portal vein to the liver before 
entering the systemic circulation. Th e term bioavailability refers to the proportion of 
the administered drug that reaches the systemic circulation and is available to have an 
eff ect. Disposition is divided into distribution and elimination. Distribution involves 
the transfer of drugs between plasma and tissues, and elimination the loss of drugs 
from the body. Most drugs are eliminated by the liver into bile or by the kidneys into 
urine.
Drug interactions are an important aspect of clinical drug treatment. Drug interactions 
can lead to severe side eff ects and such interactions have even resulted in early 
termination of drug development, refusal of approval and withdrawal from the market 
(Bjornsson et al. 2003). Th erefore, in addition to clinicians, also the pharmaceutical 
industry and regulatory authorities have paid increasing attention to drug-drug 
interactions. In pharmacokinetic drug interactions, the absorption, distribution, 
metabolism or excretion of a drug is altered. Many clinically important pharmacokinetic 
drug interactions are based on inhibition or induction of CYP enzymes. Th e 
characteristics of various CYP enzymes and their involment in the metabolism of 
commonly used drugs are now quite well established. Active membrane transporters 
have also been increasingly recognised to play an important role in pharmacokinetics 
and drug interactions (Ho and Kim 2005). Th is knowledge may provide a basis for 
better understanding and predictability of pharmacokinetic drug interactions. 
1.1. Drug metabolism
Drugs are eliminated either unchanged by the process of excretion or via 
biotransformation to metabolites. Most drugs are lipid-soluble, which promotes their 
passage through biological membranes and enables access to their site of action. Most 
lipophilic compounds are, however, eliminated poorly unless they are metabolised 
to more polar compounds (Meyer 1996). Th e metabolites are usually inactive or less 
active than the parent drug. However, some metabolites may have enhanced activity 
(prodrugs) or toxic eff ects. 
Drug biotransformation reactions can be classifi ed into phase I functionalisation 
reactions or phase II conjugation reactions. Phase I reactions introduce a functional 
group on the parent compound by oxidation, reduction or hydrolysis reactions, many 
of which are catalysed by the CYP system and require NADPH as a cofactor. Phase 
REVIEW OF THE LITERATURE
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II reactions lead to the formation of a covalent linkage between a functional group 
of the parent drug or phase I metabolite and an endogenous compound and include 
glucuronidation, sulfation, acetylation and methylation reactions. Th e enzyme systems 
involved in phase I reactions are located mainly in the endoplasmic reticulum, while 
phase II conjugating enzymes are located in both the cytoplasm and the endoplasmic 
reticulum (Krishna and Klotz 1994). 
Th e liver is the principal organ of drug metabolism, although other organs, such as the 
gastrointestinal tract, kidneys, lung and skin, can have signifi cant metabolic capacity 
(Krishna and Klotz 1994). A notable portion of a drug may be metabolised in the 
intestine or liver before entering the systemic circulation, which can signifi cantly limit 
the oral bioavailability of a drug (fi rst-pass metabolism).
Metabolic capacity can vary markedly between individuals, leading to diff erences in 
drug response and adverse eff ects among patients (Wilkinson 2005). Th e variability 
in metabolic capacity is multifactorial; gender, polymorphism of drug-metabolising 
enzymes, smoking, dietary factors and other drugs can all aff ect drug metabolism. 
1.2. CYP enzymes
Cytochrome P450 enzymes are a family of haeme-containing mono-oxygenases that 
play a major role in phase I metabolism in humans (Wrighton and Stevens 1992). 
In addition to participating in the metabolism of drugs and other xenobiotics, 
CYP enzymes have an important role in the biosynthesis and degradation of many 
endogenous compounds such as arachidonic acid and eicosanoids, steroid hormones, 
cholesterol and bile acid, vitamin D and retinoic acid (Nebert and Russell 2002). Th e 
name cytochrome P450 comes from the wavelength of light (450 nm) absorbed by 
the pigment (P) in the enzymes when the haeme iron is reduced and bound to carbon 
monoxide (Omura and Sato 1962). 
In humans, 57 cytochrome P450 genes arranged in 18 families have been identifi ed, of 
which only the CYP1, CYP2 and CYP3 families seem to contribute to the metabolism 
of drugs (Nebert and Russell 2002). CYP families are further divided into subfamilies 
and specifi c isoenzymes. All isoenzymes in the same family have at least 40% amino 
acid similarity, and those in the same subfamily have at least 55% amino acid similarity. 
Individual CYP enzymes are designated by a family number (e.g. CYP2C8), a subfamily 
letter (CYP2C8) and a number for an individual enzyme within the subfamily 
(CYP2C8)(Nelson et al. 1996).
Many in vitro studies of CYP-mediated drug metabolism in humans are conducted 
using human liver microsomes (HLM). Upon homogenisation and centrifugation 
of liver tissue, the endoplasmic reticulum is fragmented to microvesicles, which 
are referred to as microsomes. Th e microsomes contain several drug-metabolising 
enzymes, including the CYP enzymes, fl aving-containing mono-oxygenases (FMO) 
and UDP-glucuronosyltransferases (Venkatakrishnan et al. 2001).
REVIEW OF THE LITERATURE
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 1.2.1. CYP1A subfamily
Th ere are two members of the CYP1A subfamily in humans: CYP1A1 and CYP1A2. 
CYP1A1 is found primarily in extrahepatic tissues, most notably in the lung and 
placenta (Miners and McKinnon 2000). CYP1A2 is mainly a hepatic enzyme, and it 
accounts for about 12-18% of all CYP enzymes in the liver (Rowland-Yeo et al. 2004, 
Klein et al. 2006). CYP1A enzymes are inducible by xenobiotics, such as polycyclic 
aromatic hydrocarbons (PAH) found in cigarette smoke and grilled food, and the 
induction is mainly mediated by the aryl hydrocarbon receptor (AhR)(Nebert and Russell 
2002). Rifampicin has increased, for example, the clearance of CYP1A2 substrate 
mexiletine by over 60% (Pentikäinen et al. 1982), but compared with CYP3A4, CYP1A2 
seems to be only weakly induced by rifampicin in humans (Backman et al. 2006).
CYP1A2 is important in the metabolism of many drugs, including caff eine, clozapine, 
theophylline and tizanidine (Table 1)(Bertz and Granneman 1997, Miners and 
McKinnon 2000, Granfors et al. 2004). Fluvoxamine and ciprofl oxacin are strong 
inhibitors of CYP1A2 in vivo (Bertz and Granneman 1997). Furafylline is used as a 
selective CYP1A2 probe inhibitor in vitro (Miners and McKinnon 2000).
Marked interindividual variability has been reported in the activity of CYP1A2 in 
humans (Miners and McKinnon 2000). Although the CYP1A2 gene shows structural 
polymorphism (www.cypalleles.ki.se/cyp1a2.htm), its importance in explaining 
variability in CYP1A2 activity is unclear.
1.2.2. CYP2A6
CYP2A6 is the fi rst form of human CYP enzyme in the CYP2 family. CYP2A6 is a 
predominantly hepatic enzyme, and it constitutes approximately 4-8% of the total liver 
CYP content (Rowland-Yeo et al. 2004, Klein et al. 2006). Coumarine and nicotine 
are specifi c substrates of CYP2A6, and methoxsalen is a potent inhibitor of CYP2A6 
(Pelkonen et al. 2000). CYP2A6 is highly polymorphic and its genotype has been 
associated with, for example, smoking habits (Malaiyandi et al. 2005). CYP2A6 may 
be inducible by antiepileptic drugs (Pelkonen et al. 2000).
1.2.3. CYP2B6
CYP2B6 has recently received more attention as a clinically important enzyme in drug 
metabolism (Turpeinen et al. 2006). It is highly polymorphic (Lang et al. 2001), and it 
may represent up to 6% of the total CYP content in the liver (Stresser and Kupfer 1999). 
It is expressed at lower levels in some extrahepatic tissues (Ekins and Wrighton 1999). 
Clinically used substrate drugs for CYP2B6 include bupropion, cyclophosphamide, 
propofol, nevirapine and efavirenz (Hesse et al. 2000, Court et al. 2001, Ward et al. 
2003, Turpeinen et al. 2006). CYP2B6 is inducible by, for example, rifampicin (Loboz 
et al. 2006). Clopidogrel and ticlopidine are potent inhibitors of CYP2B6 (Richter et al. 
2004, Turpeinen et al. 2004, Turpeinen et al. 2005). 
REVIEW OF THE LITERATURE
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1.2.4. CYP2C subfamily
Th e human CYP2C subfamily comprises four members: CYP2C8, CYP2C9, 
CYP2C18 and CYP2C19. Of these, CYP2C8, CYP2C9 and CYP2C19 are of clinical 
importance and are collectively responsible for the metabolism of about 20% of 
clinically used drugs (Ingelman-Sundberg 2004, Totah and Rettie 2005). CYP2C 
enzymes are expressed mainly in the liver, where they account for approximately 20% 
of the total CYP content (Shimada et al. 1994), but they are expressed at a signifi cant 
level also in the small intestine (Obach et al. 2001, Läpple et al. 2003). Each member of 
the CYP2C subfamily is genetically polymorphic (Daly 2003).
Th e importance of CYP2C8 in drug metabolism is being increasingly recognised, and 
it has a major role in the metabolism of a growing number of substrates, including 
paclitaxel, repaglinide, rosiglitazone, pioglitazone, cerivastatin, amiodarone, 
amodiaquine, chloroquine and arachidonic acid (Eckland and Danhof 2000, Totah and 
Rettie 2005). Some overlapping substrate specifi city appears to exist between CYP2C8 
and CYP3A4 in, for instance, the metabolism of carbamazepine, cerivastatin and 
repaglinide (Ong et al. 2000, Totah and Rettie 2005). CYP2C8 constitutes about 7% 
of total microsomal CYP content in the liver, and CYP2C8 protein has been detected 
in several extrahepatic tissues as well (Enayetallah et al. 2004, Totah and Rettie 2005). 
CYP2C8 is inducible by rifampicin, phenobarbital and dexamethasone in vitro 
(Gerbal-Chaloin et al. 2001, Madan et al. 2003). Montelukast is a very selective and potent 
CYP2C8 inhibitor in vitro (Walsky et al. 2005b). Gemfi brozil (gemfi brozil glucuronide) 
and trimethoprim inhibit CYP2C8 both in vitro and in vivo (Backman et al. 2002, Wang 
et al. 2002, Wen et al. 2002, Niemi et al. 2003b, Niemi et al. 2003c, Niemi et al. 2004a, Ogilvie 
et al. 2006). Although the most common variant alleles CYP2C8*2 and CYP2C8*3 
show decreased enzyme activity in vitro, the clinical consequences of the polymorphism 
have not been fully determined (Totah and Rettie 2005).
CYP2C9 is the predominant CYP2C enzyme in both the intestine and the liver 
(Läpple et al. 2003). CYP2C9 is estimated to be responsible for the metabolism of 
up to 15% of all drugs that undergo phase I metabolism, and its substrates include 
S-warfarin, phenytoin, losartan, fl uvastatin, sulphonylurea antidiabetic drugs and 
several NSAIDs (Rettie and Jones 2005). Sulfaphenazole is a selective and potent 
CYP2C9 inhibitor (Miners and Birkett 1998). Clinically signifi cant inhibition may occur 
also with coadministration of amiodarone, fl uconazole, miconazole, voriconazole 
and certain other sulphonamides (Miners and Birkett 1998, Th euretzbacher et al. 
2006). CYP2C9 activity in vivo is inducible by rifampicin (Miners and Birkett 1998). 
Genetic polymorphism of CYP2C9 aff ects warfarin, phenytoin and sulphonylurea 
drug dose requirements and has been associated with an increased risk of bleeding 
complications during warfarin treatment (van der Weide et al. 2001, Higashi et al. 2002, 
Kirchheiner et al. 2005). Th e most common allelic variants with reduced catalytic 
activity are CYP2C9*2 and CYP2C9*3, and they have allele frequencies of 11% and 
7%, respectively, in Caucasians (Kirchheiner and Brockmöller 2005).
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CYP2C19 metabolises proton pump inhibitors, some antidepressants, diazepam, 
proguanil and propranolol, among others (Desta et al. 2002). Omeprazole has been 
used as a probe inhibitor of CYP2C19 both in vitro and in vivo (Ko et al. 1997, 
Desta et al. 2002). Other drugs, such as fl uoxetine, fl uvoxamine, ticlopidine and 
isoniazid, can also inhibit the metabolism of CYP2C19 substrate drugs (Desta 
et al. 2002). Rifampicin and artemisinin have been identifi ed as inducers of 
CYP2C19 (Desta et al. 2002). Approximately 3-5% of Caucasians and up to 20% of 
Asian populations are poor metabolisers of CYP2C19 substrates (Desta et al. 2002). 
CYP2C19 genotype has been shown to aff ect the effi  cacy of proton pump inhibitor 
treatments (Klotz et al. 2004).
1.2.5. CYP2D6
CYP2D6 is the only functionally active isoenzyme in the CYP2D subfamily in humans. 
Although it constitutes only 2-5% of total CYP content in the liver, it is responsible 
for up to 25% of the metabolism of known drugs (Zanger and Eichelbaum 2000, 
Ingelman-Sundberg 2005). At lower levels, CYP2D6 is expressed in extrahepatic 
tissues, including the gastrointestinal tract and brain (Zanger et al. 2004). CYP2D6 is 
polymorphically expressed, with four existing phenotypes that defi ne the rate of drug 
metabolism by CYP2D6; poor metabolisers (PM), who lack the functional enzyme, 
intermediate metabolisers (IM), who have at least one partially defi cient allele, extensive 
metabolisers (EM), who have two normal alleles, and ultrarapid metabolisers (UM), 
who have multiple gene copies. Up to 10% of Caucasians are poor metabolisers of 
CYP2D6 (Zanger et al. 2004).
CYP2D6 substrates include many tricyclic antidepressants, selective serotonin 
reuptake inhibitors (SSRIs), neuroleptics, beta-blockers and opiates (Zanger et al. 
2004). Quinidine, paroxetine, fl uoxetine, fl uvoxamine, moclobemide, fl ecainide and 
terbinafi ne are potent inhibitors of CYP2D6 (Abdel-Rahman et al. 1999, Zanger et al. 
2004). In contrast to all other CYP enzymes involved in drug metabolism, CYP2D6 is 
not known to be inducible (Ingelman-Sundberg 2005).
1.2.6. CYP2E1
CYP2E1 accounts for about 14-17% of hepatic CYP content (Rowland-Yeo et 
al. 2004, Klein et al. 2006). Th is isoenxyme has mainly toxicological relevance, 
since it can bioactivate many compounds to carcinogens and reactive metabolites 
(Raycy and Carpenter 2000). It takes part in the metabolism of ethanol, disulfi ram, 
paracetamol, anaesthetics such as halothane, enfl urane, isofl urane and sevofl urane, 
and chlorzoxazone, which serves as a probe of CYP2E1 activity (Raycy and Carpenter 
2000, Anzenbacher and Anzenbacherová 2001). Ethanol and isoniazid are known 
inducers of CYP2E1 (Raycy and Carpenter 2000). Disulfi ram is reduced by CYP2E1 to 
diethyldithiocarbamate (DDC)(Raycy and Carpenter 2000), which is used as an in 
vitro inhibitor of CYP2E1 (Eagling et al. 1998).
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1.2.7. CYP3A subfamily
CYP3A enzymes are the most important oxidative enzymes in human drug metabolism. 
Th ey have been estimated to participate in the metabolism of 40-50% of all drugs 
(Pelkonen et al. 1998, Wrighton et al. 2000, Ingelman-Sundberg 2004). Th e isoforms 
of CYP3A in humans include CYP3A4, CYP3A5, CYP3A7 and CYP3A43. 
CYP3A4 is the most abundant CYP enzyme in both the small intestinal mucosa 
and the liver, where it accounts for almost 30% of total CYP content (Shimada et 
al. 1994, Wrighton and Th ummel 2000). Its substrates include the calcium-channel 
blockers nifedipine, felodipine, diltiazem and verapamil, the HMG-CoA reductase 
inhibitors atorvastatin, lovastatin and simvastatin, the HIV protease inhibitors, the 
PDE5 inhibitors such as sildenafi l, and the benzodiazepines alprazolam, midazolam 
and triazolam (Dresser et al. 2000). Hepatic and intestinal CYP3A4 can be induced 
by several drugs, such as carbamazepine, phenytoin and rifampicin, and St. John’s 
wort (Hypericum Perforatum) (Backman et al. 1996a, Backman et al. 1996b, Dürr et 
al. 2000, Wrighton and Th ummel 2000). Th ere are many known potent inhibitors of 
CYP3A4, including the azole antifungals ketoconazole, itraconazole and voriconazole, 
the macrolide antibiotics clarithromycin, erythromycin and troleandomycin, the 
calcium-channel blockers diltiazem and verapamil, the HIV protease inhibitors and 
grapefruit juice (Dresser et al. 2000, Wrighton and Th ummel 2000, Th euretzbacher et 
al. 2006). Although the activity of CYP3A4 varies greatly, its population distribution 
is unimodal and genetic polymorphisms do not appear to explain the interindividual 
variation (Wilkinson 2005). 
CYP3A5 is signifi cantly expressed in only about 10-20% of Caucasian livers (Lamba 
et al. 2002). It is also found in extrahepatic tissues and is the dominant CYP3A form 
in the human kidney (Wrighton and Th ummel 2000). In individuals expressing 
CYP3A5, the contribution relative to the total hepatic CYP3A seems to range from 
17% to 50% (Daly 2006). CYP3A7 is present primarily in foetal tissues, representing 
about 50% of the total CYP in foetal liver (Wrighton and Th ummel 2000). It is also 
expressed in some adult livers (Daly 2003). Th e substrate specifi cities of CYP3A5 
and CYP3A7 are, in general, similar to that of CYP3A4 (Wrighton and Th ummel 2000). 
Variable expression of CYP3A5 and CYP3A7 may account in part for the variation in 
the metabolism of CYP3A4 substrates (Daly 2003). CYP3A43 is expressed in relatively 
high levels in the prostate and testes, but its expression in the liver is low. Th e functional 
role and substrate specifi city of CYP3A43 are currently unknown (Daly 2006).
1.3. Induction and inhibition of CYP enzymes
Induction has been suggested to be an adaptive process in which prolonged exposure 
to drugs or other chemicals causes an up-regulation in the amount of enzymes that are 
capable of metabolising the inducing agent. Since induction aff ects the rate of protein 
synthesis (or degradation), a steady state with respect to induction is generally reached 
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in two to three weeks. Th e disappearance of the induction eff ect (wash-out period) aft er 
discontinuation of the inducing agent can also take several weeks (Wilkinson 2005). 
Induction of drug-metabolising enzymes may increase the elimination and reduce the 
bioavailability of the substrate drug, and correspondingly, decrease the drug’s plasma 
concentration. In contrast, for drugs that are metabolised to active or reactive metabolites, 
induction can lead to enhanced drug eff ects or toxicity (Pelkonen et al. 1998).
Inhibition of drug-metabolising enzymes can lead to increased plasma concentration 
of the substrate drug, and thus, exaggerated and prolonged pharmacological eff ects. 
Th is increases the likelihood of adverse eff ects and drug toxicity, especially with 
drugs that are extensively metabolised and have a narrow therapeutic index, unless 
appropriate dose reductions are made. In the case of prodrugs requiring metabolic 
activation, inhibition can reduce the clinical effi  cacy of the substrate drug. Contrary 
to induction, inhibition may occur immediately aft er one or two doses of the inhibitor 
(Lin and Lu 1998).
1.3.1. Mechanisms of induction 
Induction of drug-metabolising enzymes is mainly mediated by intracellular nuclear 
receptors. Th ese include the pregnane X receptor (PXR), the constitutive androstane 
receptor (CAR) and the aryl hydrocarbon receptor (AhR)(Handschin and Meyer 
2003). 
PXR and CAR mediate the induction of CYP2 and CYP3 enzymes, but phase II 
conjugative enzymes and drug transporters can also be induced (Honkakoski et al. 
2003). Th e mechanism of induction involves binding of the inducing agent to PXR 
or CAR. Th e complex then forms a heterodimer with the retinoid X receptor (RXR), 
which in turn binds to DNA-responsive element and enhances the transcription of 
the target gene (Willson and Kliewer 2002). PXR and CAR seem to have fl exible 
and overlapping binding specifi cities, and they can activate each other’s target genes. 
Human PXR is activated by a wide range of structurally diverse chemicals, such as 
rifampicin, ritonavir and hyperforin, and phenobarbital has been shown to activate 
human CAR (Honkakoski et al. 2003). Both PXR and CAR are abundantly expressed 
in the liver and intestine, with little expression appearing in other tissues. 
Polycyclic aromatic hydrocarbon compounds found in tobacco smoke and grilled food 
induce drug-metabolising enzymes by binding to the AhR. Th is complex, together 
with another protein, AhR nuclear translocator (Arnt), increases enzyme expression 
by binding to the target gene’s responsive element. Th is mechanism activates mainly 
CYP1A1 and CYP1A2, but the concentrations of glutathione S-transferase and UDP-
glucuronosyltransferase enzymes are also increased (Fuhr 2000).
Other known nuclear receptors, including the farnesoid X receptor (FXR) and the 
peroxisome proliferator activated receptor (PPAR), have also been shown to take part 
in regulating the expression of drug disposition genes (Dixit et al. 2005).
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Contrary to nuclear receptor-mediated induction, ethanol can induce CYP2E1 by 
stabilisation of the enzyme, which results in accumulation of CYP2E1 (Fuhr 2000).
1.3.2. Mechanisms of inhibition
Th e clinically relevant mechanisms of CYP inhibition can be divided into reversible 
and irreversible inhibition (mechanism-based inactivation) (Zhang and Wong 2005). 
Based on enzyme kinetics, reversible inhibition can be categorised into competitive, 
uncompetitive, noncompetitive and mixed inhibition (Zhang and Wong 2005). 
In competitive inhibition, the inhibitor binds to the enzyme at the same site as the 
substrate and subsequently blocks the substrate binding; the substrate and inhibitor 
compete for the enzyme’s active site. Th is type of inhibition can be overcome by 
increasing concentrations of the substrate. Competitive inhibitors oft en have similar 
structures as the substrate drugs. In uncompetitive inhibition, the inhibitor binds 
eff ectively only to the enzyme-substrate complex and makes the complex catalytically 
inactive. In noncompetitive inhibition, the inhibitor binds to the enzyme with the same 
affi  nity in both unbound and substrate-bound forms, reducing its catalytic activity. As 
a result, the extent of inhibition depends only on the concentration of the inhibitor. In 
mixed inhibition, the inhibitor can bind with diff erent affi  nities to the enzyme or to the 
enzyme-substrate complex, thus interfering with the substrate binding and vice versa. 
High substrate concentrations can reduce but not overcome mixed inhibition.
In irreversible inhibition, drugs with reactive functional groups are metabolised by 
CYP enzymes to reactive intermediates that covalently modify the CYP enzyme, 
and inhibition cannot therefore be reversed (Lin and Lu 1998). Because metabolic 
activation is required, these drugs are oft en called mechanism-based inactivators or 
suicide substrates. Binding of an irreversible inhibitor to the enzyme can be prevented 
by competition with a substrate or a reversible inhibitor. 
1.4. Drug transporters
It has become increasingly evident that active drug transport systems infl uence the 
pharmacokinetics of many drugs by controlling their movement into and out of cells 
(Giacomini and Sugiyama 2006). Transporters work in concert with drug-metabolising 
enzymes, and it is thus oft en appropriate to consider together the impact of CYP-
mediated drug metabolism and transporter-mediated drug effl  ux and uptake when 
making assessments of drug pharmacokinetics (Ho and Kim 2005). Drug interactions 
can occur when induction or inhibition of drug transporters alter e.g. intestinal 
absorption, proximal renal-tubular excretion, biliary excretion or penetration 
across the blood-brain barrier of substrate drugs (Giacomini and Sugiyama 2006). 
Th e best-known drug transport systems that play a role in drug interactions are the 
P-glycoprotein (MDR1, multidrug resistance protein 1) and human organic anion-
transporting polypeptides (OATPs)(DuBuske 2005).
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Th e P-glycoprotein is a transmembrane protein that operates as an effl  ux pump to export 
drugs out of cells. It facilitates excretion of substances into urine, bile and intestinal 
lumen (i.e. reduced absorption) and prevents excess accumulation in the brain (Fromm 
2003). Th ere is overlapping specifi city between CYP3A4 and P-glycoprotein substrates 
and inhibitors (Ayrton and Morgan 2001). Substrate drugs for P-glycoprotein include 
anticancer drugs, HIV protease inhibitors, steroids, digoxin, quinidine, cyclosporine 
and loperamide (Giacomini and Sugiyama 2006). Quinidine, erythromycin, verapamil 
and itraconazole are known inhibitors of P-glycoprotein (DuBuske 2005, Ho and Kim 
2005). P-glycoprotein is inducible by, for example, rifampicin and St. John’s wort 
(Fromm 2003).
OATPs are a class of transmembrane proteins that are expressed in human intestine, 
liver, kidney and brain tissue (Ho and Kim 2005). In contrast to the P-glycoprotein, 
OATPs act as drug uptake pumps, transporting drugs into cells. Substrates for members 
of the OATP subfamily include bile salts, hormones, HMG-CoA reductase inhibitors, 
digoxin and methotrexate (Ho and Kim 2005, Shitara et al. 2005). 
Many agents that aff ect P-glycoprotein function also aff ect OATP activity. Coordinate 
activity of both drug uptake and effl  ux transporters may determine the net absorption 
and subsequent elimination of a drug (Kim 2003). In addition to drug-induced 
changes in P-glycoprotein and OATP activity, these transporters also exhibit genetic 
polymorphism (Ho and Kim 2005, König et al. 2006). 
2. Pioglitazone
Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-]- thiazoli-
dinedione monohydrochloride] is a thiazolidinedione class antidiabetic drug that acts 
primarily by decreasing insulin resistance. Th e thiazolidinediones (or “glitazones”) 
were introduced in the late 1990s as an adjunctive therapy for type 2 diabetes. Th e 
fi rst member of the class, troglitazone (Rezulin®), was rapidly withdrawn from the 
market because of fulminant drug-induced hepatitis (Gale 2001). Th e other two 
compounds, pioglitazone (Actos®) and rosiglitazone (Avandia®), appear to be devoid 
of idiosyncratic liver toxicity (Yki-Järvinen 2004).
2.1. Pharmacodynamics and clinical use
Pioglitazone is a ligand for peroxisome proliferator activated receptor-γ (PPAR-γ), 
a member of the nuclear receptor superfamily. Once activated by pioglitazone, PPAR-γ
forms a heterodimer with the retinoid X receptor. Th e heterodimer then binds to 
specifi c DNA sequences and regulates the target genes involved in the metabolism of 
glucose and lipids. Th e activation of PPAR-γ leads to increased insulin sensitivity in 
hepatic, fat and skeletal muscle cells, thereby inhibiting hepatic gluconeogenesis and 
increasing peripheral glucose uptake. However, the exact mechanism remains obscure. 
Pioglitazone is not an insulin secretagogue, and it is dependent on the presence of 
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insulin to exert its eff ects. In addition to its action on glucose metabolism, pioglitazone 
promotes the diff erentiation of adipocytes, which leads to redistribution of lipid from 
visceral to subcutaneous deposits (Waugh et al. 2006).
In Europe, pioglitazone is approved as monotherapy and in combination with 
metformin or sulphonylurea for treatment of patients with type 2 diabetes. Pioglitazone 
is taken orally once daily at a dosage of 15 or 30 mg/day, with titration to 45 mg/day if 
necessary (Waugh et al. 2006). At maximal dose, pioglitazone decreases glycosylated 
haemoglobin value (HbA1c) on average by 1-1.5% (Yki-Järvinen 2004). Th e blood 
glucose lowering eff ect of pioglitazone develops gradually over weeks, with a maximal 
decrease in blood glucose being reached aft er 10-14 weeks (Aronoff  et al. 2000).
2.2. Pharmacokinetics and drug interactions
Pioglitazone is rapidly absorbed from the gastrointestinal tract, with peak plasma 
concentrations (Cmax) observed within two hours (Eckland and Danhof 2000). Food 
slightly delays the time to peak concentration (tmax), but does not alter the extent of 
absorption (Waugh et al. 2006). Th e mean absolute oral bioavailability of pioglitazone is 
83% (Eckland and Danhof 2000). Pioglitazone is extensively (97% to over 99%) bound 
to plasma proteins, primarily to albumin, and has a rather small apparent volume of 
distribution (0.63 l/kg) (Eckland and Danhof 2000, Waugh et al. 2006). 
In humans, pioglitazone is extensively metabolised by hydroxylation and oxidation to 
fi ve primary metabolites (M-I, M-II, M-IV, M-V and M-VI), and by further oxidation 
of M-IV to a secondary metabolite M-III (Figure 1)(Eckland and Danhof 2000, Baba 
2001). In addition, four minor metabolites (M-VII to M-X) have been identifi ed in 
vitro and in animals (Shen et al. 2003). Th e hydroxy derivates of pioglitazone, M-II and 
M-IV, and the keto derivate M-III have been shown to be pharmacologically active in 
animal models. M-IV and M-III are the principal metabolites found in human serum, 
and at steady state they comprise approximately 75-80% of the total AUC of active 
compounds (Actos prescribing information, Baba 2001). M-II is found at relatively 
low concentrations in plasma, and it does not signifi cantly contribute to total active 
compounds (Eckland and Danhof 2000). M-IV and M-III are highly (>98%) bound 
in plasma proteins (Waugh et al. 2006). Th e mean elimination half-life of pioglitazone 
ranges from 3 to 9 hours (Eckland and Danhof 2000, Baba 2001), but the half-life of 
the active metabolites M-IV and M-III is considerable longer (26-28 hours), which 
is likely to contribute to an extended pharmacological activity that allows for once 
daily administration of pioglitazone (Eckland and Danhof 2000). Following oral 
administration, approximately 15-30% of the pioglitazone dose is recovered in the 
urine. However, renal elimination of the parent pioglitazone is negligible, and the drug 
is primarily excreted as metabolites and their conjugates (Waugh et al. 2006). Th e main 
compound excreted in urine is M-V (Eckland and Danhof 2000). Age and gender 
have no signifi cant eff ect on the pharmacokinetics of pioglitazone (Waugh et al. 2006). 
Overall, the pharmacokinetics of pioglitazone in patients with type 2 diabetes is similar 
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to that in healthy volunteers (Eckland and Danhof 2000). 
In vitro studies with HML have suggested that multiple CYP isoenzymes (1A1, 1A2, 
2C8, 2C9, 2C19, 2D6 and 3A4) are involved in the metabolism of pioglitazone, with the 
most important isoenzymes reported to be CYP2C8, CYP2C9 and CYP3A4 (Eckland 
and Danhof 2000, Hanefeld 2001). CYP2C8 and CYP3A4 are reported to contribute 
approximately 40% and less than 20%, respectively, to the metabolism of pioglitazone 
and M-IV (Hanefeld 2001). However, the information on the contribution of diff erent 
CYP isoforms to the metabolism of pioglitazone seems to be based on unpublished 
data, and the experimental systems in which these results were obtained, have not been 
described. In addition, information from diff erent sources appears to be discrepant. For 
example, the Finnish product information has previously stated that the metabolism 
of pioglitazone occurs predominantly via CYP3A4 and CYP2C9 (Pharmaca Fennica: 
Actos), whereas the US label states that the major CYP isoforms involved are CYP2C8 
and CYP3A4 (Actos prescribing information). Prior to this thesis, no published studies 
have been available on the eff ects of CYP enzyme inducers or CYP2C8 inhibitors on 
the pharmacokinetics of pioglitazone in vivo.
Pioglitazone has been reported to both inhibit (testosterone 6β-hydroxylation, 
Ki 11.8 µM) and induce CYP3A4 activity in vitro (Sahi et al. 2003). In healthy 
volunteers, pioglitazone has not altered CYP3A4 marker activity (urinary excretion 
ratio of 6β-hydroxycortisol to cortisol) or aff ected the pharmacokinetics of CYP3A4 
substrate simvastatin signifi cantly, suggesting that pioglitazone is not a signifi cant 
inducer or inhibitor of CYP3A4 in vivo (Prueksaritanont et al. 2001, Nowak et al. 2002). 
Pioglitazone has also been reported to inhibit CYP2C9 (tolbutamide hydroxylation, 
Ki 32.1 µM) in vitro, but it has not altered the pharmacokinetics of drugs metabolised 
mainly by CYP2C9 (warfarin, glibenclamide, glipizide) in vivo (Gillies and Dunn 
2000).
In vitro, pioglitazone has most potently inhibited CYP2C8 (paclitaxel 6α-hydroxylation, 
Ki 1.7 µM; amodiaquine N-deethylation, IC50 11.7 µM) (Sahi et al. 2003, Walsky et al. 
2005a). However, no studies have been published on the eff ect of pioglitazone on the 
pharmacokinetics of CYP2C8 substrate drugs in humans.
Pioglitazone has been reported to inhibit OATP1B1 and OATP1B3 in vitro, suggesting 
that pioglitazone could also be a substrate for these transporters (Nozawa et al. 2004). 
To date, the eff ect of genetic polymorphism in CYP2C8 or drug transporters on 
pioglitazone metabolism has not been studied (Kirchheiner et al. 2005).
2.3. Adverse eﬀ ects
Common adverse eff ects of pioglitazone include weight gain, fl uid retention and plasma 
volume expansion, which can produce mild dilutional anaemia, peripheral oedema and 
can lead to or exacerbate heart failure (Waugh et al. 2006). Th e underlying mechanism 
of fl uid retention has not been fully elucidated, but it appears to be a dose-related class 
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eff ect of thiazolidinediones (Macfarlane and Fisher 2006). Th e risk of oedema and 
heart failure is higher when thiazolidinediones are combined with insulin (Nesto et al. 
2004). Th e manufacturer of pioglitazone  reports an incidence of peripheral oedema 
of 4.8% for monotherapy and 5.9-7.2% for combination therapy with metformin or 
sulphonylurea, increasing to 15.3% for combination treatment with insulin (Waugh 
et al. 2006). In a recently published large study, oedema in the absence of heart failure 
was experienced by 21% of pioglitazone recipients versus 13% of placebo recipients, 
and heart failure occurred signifi cantly more oft en in pioglitazone recipients (11%) 
than in placebo recipients (8%; P < 0.0001) (Dormandy et al. 2005). Heart failure and 
insulin therapy are contraindications to the use of thiazolidinediones in Europe.
Unlike troglitazone, pioglitazone has rarely been associated with hepatotoxicity or 
elevated liver enzymes. Th ere have been a few reports of liver injury with pioglitazone, 
but direct causality has not been established (Waugh et al. 2006).
Recent studies have suggested that exposure to thiazolidinediones has important 
eff ects on bone.  In rodent models, activation of PPAR-γ by thiazolidinediones has 
stimulated adipocyte formation from the mesenchymal precursor cells at the expense 
of the formation of osteoblasts, resulting in bone loss (Marie and Kaabeche 2006). 
Recent data from an observational study in older adults with diabetes suggest that 
thiazolidinedione use is associated with an increased rate of bone loss in women 
(Schwartz et al. 2006). Another randomised, controlled study found that short-term 
rosiglitazone treatment inhibits bone formation and accelerates bone loss in healthy 
postmenopausal women (Grey et al. 2007). In addition, a safety analysis of a large, 
controlled clinical trial revealed that signifi cantly more female patients who received 
rosiglitazone experienced fractures than did females who received either metformin 
or glibenclamide (Kahn et al. 2006). Th e majority of the fractures observed in the 
rosiglitazone group were in the humerus, hand and foot. Th e number of women with 
hip or spine fractures was low and did not diff er between the groups.   
3. Drugs studied with pioglitazone in vivo
3.1. Rifampicin
Rifampicin is a bactericidal antibiotic drug of the rifamycin class that acts by inhibiting 
RNA polymerase in bacterial cells (Campbell et al. 2001). It is used mainly to treat 
tuberculosis (Douglas and McLeod 1999), but it has also a role in the treatment of 
e.g. staphylococcal infections. Th e dosage of rifampicin is usually between 450 and 
600 mg once daily.
Rifampicin is readily absorbed, with therapeutic concentrations achieved in 2-4 hours 
aft er oral administration. Rifampicin induces its own metabolism and the half-life, 
which is between 2 and 5 hours on initiation of therapy, decreases to 2-3 hours aft er 
repeated administration (Douglas and McLeod 1999). Rifampicin is metabolised by 
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deacetylation. Both unchanged rifampicin and desacetylrifampicin are excreted in the 
bile and urine, and unchanged rifampicin is reabsorbed into enterohepatic circulation. 
Rifampicin is 60-80% protein bound (Dollery 1999).
Th e most common adverse eff ects of rifampicin are gastrointestinal disturbances, rash 
and fever, and rifampicin can cause body fl uids, such as urine and tears, to become 
reddish in colour. Rifampicin has been shown to produce liver dysfunction, particularly 
in patients with chronic liver disease or in patients taking other hepatotoxic agents 
(Dollery 1999).
Rifampicin is a potent inducer of several drug-metabolising enzymes and the 
P-glycoprotein, and it can markedly (more than 10-fold) reduce the plasma 
concentrations of many drugs, particularly drugs with signifi cant presystemic 
metabolism (Niemi et al. 2003a). Rifampicin has its greatest eff ects on the expression of 
CYP3A4 in the liver and small intestine (Niemi et al. 2003a), but it also induces CYP2C 
enzymes in human hepatocytes and small bowel enterocytes (Gerbal-Chaloin et al. 
2001, Raucy et al. 2002, Madan et al. 2003, Glaeser et al. 2005). Drug interaction studies 
in humans indicate that rifampicin induces CYP2C enzymes also in vivo (Niemi et al. 
2003a). For example, rifampicin has been found to decrease the AUCs of antidiabetics 
rosiglitazone (CYP2C8 and CYP2C9 substrate) and repaglinide (CYP2C8 and CYP3A4 
substrate) by over 50% (Niemi et al. 2000, Niemi et al. 2004a, Park et al. 2004a).
3.2. Itraconazole
Itraconazole is a triazole antifungal agent that interferes with fungal cell membrane 
ergosterol synthesis by inhibiting the fungal cytochrome P450 enzyme lanosterol 
14-demethylase (Grant and Clissold 1989). In addition to inhibiting the fungal enzyme, 
all azoles can also inhibit human drug-metabolising CYP enzymes, thereby impairing 
the metabolism of many drugs (Backman et al. 2000).
Itraconazole is available as an oral capsule and as a solution, with recommended daily 
doses ranging from 100 to 400 mg. Optimal absorption of itraconazole capsules is 
achieved when these are taken with a meal (De Beule and Van Gestel 2001). Itraconazole 
is tightly bound to plasma albumin and blood cells, leaving only 0.2% of the drug 
free in plasma. Itraconazole is highly lipophilic and despite high protein binding, 
its concentrations within tissues are considerable, with a large apparent volume of 
distribution (about 11 l /kg). Tissues such as skin, nails and liver accumulate itraconazole 
(Grant and Clissold 1989). Itraconazole seems to be metabolised by CYP3A4 (Tucker 
et al. 1992, Isoherranen et al. 2004). Th e major metabolite, hydroxyitraconazole, 
reaches about 2-fold higher plasma concentrations than the parent compound and 
has considerable antifungal activity. Elimination of itraconazole is biphasic, with a 
terminal t½ of approximately 20 hours aft er a single dose. At steady state, the terminal 
t½ increases to 30 hours, indicating that the elimination of itraconazole is a saturable 
process at clinical doses (Grant and Clissold 1989). Th e most common adverse eff ects 
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of itraconazole are gastrointestinal disturbances, dizziness, pruritus, headache and 
mild increase in liver enzymes (Grant and Clissold 1989). 
Itraconazole and hydroxyitraconazole are potent CYP3A4 inhibitors in vitro (Back 
and Tjia 1991, von Moltke et al. 1996, Wang et al. 1999, Isoherranen et al. 2004). In 
vivo, itraconazole greatly (i.e., 4- to over 25-fold) increases the plasma concentrations 
of many drugs that are metabolised mainly by CYP3A4, such as midazolam and 
triazolam (Olkkola et al. 1994, Varhe et al. 1994, Backman et al. 2000). Itraconazole 
also inhibits the P-glycoprotein, consequently raising the concentrations of digoxin 
(Partanen et al. 1996, DuBuske 2005). In addition, itraconazole has recently been 
reported to inhibit CYP2B6 in vitro (Walsky et al. 2006). Th ere are relatively few in vivo 
studies of the eff ects of itraconazole on enzymes other than CYP3A4, but it seems to 
have no signifi cant inhibitory eff ect on CYP1A2, CYP2C9 or CYP2C19 (Backman et 
al. 2000). In pharmacokinetic interaction studies, itraconazole has increased the AUCs 
of the antidiabetic drugs (partially metabolised by CYP3A) repaglinide (CYP2C8 and 
CYP3A4 substrate) and nateglinide (CYP2C9 and CYP3A4 substrate) by 40-50% 
(Niemi et al. 2003c, Niemi et al. 2005a). In addition, itraconazole has raised the AUC 
of loperamide, a substrate of CYP2C8, CYP3A4 and the P-glycoprotein, almost 4-fold 
(Niemi et al. 2006).
3.3. Gemﬁ brozil
Gemfi brozil is a fi bric acid derivate that reduces plasma triglyceride concentrations and 
slightly increases HDL cholesterol levels (Frick et al. 1987), most likely due to induction 
of fatty acid oxidation through activation of PPAR-α (Lee et al. 2003). Gemfi brozil is 
used mainly in the treatment of hypertriglyceridaemia with a recommended dose of 
600 mg twice daily.
Th e absorption of gemfi brozil is almost complete, and peak plasma concentrations 
are attained in 1-2 hours aft er administration (Todd and Ward 1988). Gemfi brozil is 
at least 97% bound to plasma proteins. It is eliminated mainly by metabolism with 
a mean elimination t½ of 7.6 hours. Both unchanged gemfi brozil and its metabolites 
form glucuronide conjugates. Th e most common adverse eff ects of gemfi brozil are 
gastrointestinal symptoms and rash (Todd and Ward 1988).
Gemfi brozil is one of the most potent inhibitors of CYP2C8 in humans, and there 
have been several reports of clinical interactions between gemfi brozil and CYP2C8 
substrates; for example, repaglinide (8.1-fold increase in AUC), cerivastatin (5.6-fold 
increase in AUC), rosiglitazone (2.3-fold increase in AUC) and loperamide (2.2-
fold increase in AUC)(Backman et al. 2002, Niemi et al. 2003c, Niemi et al. 2003b, 
Niemi et al. 2006). In vitro, gemfi brozil has potently inhibited CYP2C9 (tolbutamide 
hydroxylation, Ki 5.8 µM), whereas its inhibitory eff ect towards CYP2C8 has been 
substantially weaker (paclitaxel 6α-hydroxylation, Ki 75 µM) (Wen et al. 2001, Wang 
et al. 2002). However, in humans, the eff ects of gemfi brozil on CYP2C9-mediated 
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metabolism have been smaller or even lacking (Niemi et al. 2001b, Lilja et al. 2005, 
Niemi et al. 2005a). Recent studies have demonstrated that a major metabolite of 
gemfi brozil, gemfi brozil glucuronide, is a rather selective and more potent inhibitor of 
CYP2C8 (paclitaxel 6α-hydroxylation, IC50 1.8 µM aft er a 30-min preincubation) than 
the parent gemfi brozil, indicating that the interactions of gemfi brozil in vivo are, at 
least in part, due to the metabolite (Shitara et al. 2004, Ogilvie et al. 2006). Gemfi brozil 
also inhibits OATP1B1, which could partially explain the gemfi brozil-cerivastatin and 
gemfi brozil-repaglinide interactions (Shitara et al. 2004).
3.4. Montelukast and zaﬁ rlukast
Montelukast and zafi rlukast are leukotriene receptor antagonists that are both anti-
infl ammatory and bronchodilatory. Th ey are used orally as adjunctive therapy in 
asthma and allergic rhinitis. Th e recommended doses of montelukast and zafi rlukast 
are 10 mg once daily and 20 mg twice daily, respectively. Th eir most common adverse 
eff ects are headache and gastrointestinal symptoms (Lipworth 1999).
Th e peak plasma concentrations of montelukast are achieved in 3-4 hours and its 
oral bioavailability is approximately 64% (Markham and Faulds 1998). Montelukast 
is more than 99% bound to plasma protein (Singulair prescribing information). It is 
extensively metabolised and its t½ ranges from 2.7 to 5.5 hours (Markham and Faulds 
1998). CYP2C9 and CYP3A4 are involved in the metabolism of montelukast in vitro 
(Singulair prescribing information). Montelukast has recently been found to be a very 
potent and selective CYP2C8 inhibitor in vitro, with a Ki value ranging from 0.0092 
to 0.15 µM depending on the microsomal protein concentration (Walsky et al. 2005a, 
Walsky et al. 2005b). 
Peak plasma concentrations of zafi rlukast are achieved within 3 hours of oral 
administration. Zafi rlukast is over 99% bound to plasma proteins and has a terminal 
t½ of approximately 10 hours. It undergoes extensive hepatic metabolism, with 
CYP2C9 as the major biotransformation pathway. Zafi rlukast has been reported to 
inhibit CYP2C9 and CYP3A4 in vitro (Dekhuijzen and Koopmans 2002). Zafi rlukast 
has also recently been found to inhibit CYP2C8 in vitro, with an IC50 value of 
0.388 µM (amodiaquine N-deethylation) (Walsky et al. 2005a).
According to previous predictions based on in vitro inhibition data and therapeutic 
plasma montelukast concentrations, the expected magnitude of its eff ect on a CYP2C8 
cleared drug has ranged from a 2-fold to over a 100-fold increase in AUC, depending 
on whether unbound (assuming 1% free fraction) or total montelukast concentration 
has been used in the prediction (Walsky et al. 2005b). Th e in vitro inhibitory potency 
and the circulating concentrations of zafi rlukast have suggested a possibility of weak 
CYP2C8 inhibition in vivo (Walsky et al. 2005a). At the time of this work, no studies 
were published on the eff ects of montelukast or zafi rlukast on the pharmacokinetics of 
CYP2C8 substrate drugs in vivo.
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3.5. Repaglinide
Repaglinide is a fast-acting prandial oral antidiabetic agent belonging to the 
meglitinide family. It lowers blood glucose by enhancing insulin release from 
pancreatic β-cells (Hatorp 2002). Repaglinide is used in type 2 diabetes, with a 
recommended dose range of 0.5-4 mg before each meal (maximum daily dose 16 mg) 
(Prandin prescribing information). Th e most common adverse eff ect of repaglinide 
is hypoglycaemia (Culy and Jarvis 2001). 
Aft er oral administration, repaglinide is rapidly absorbed, with Cmax occurring 
within 1 hour. Th e mean absolute bioavailability is about 60% (Hatorp 2002), 
suggesting considerable fi rst-pass metabolism. Repaglinide is highly (>98%) bound 
to plasma proteins. It is cleared rapidly from the circulation, with a half-life of 
approximately 1 hour (Hatorp 2002). Repaglinide is extensively metabolised in 
the liver. Th e most important enzymes participating in the biotransformation of 
repaglinide in vitro are CYP2C8 and CYP3A4 (Bidstrup et al. 2003, Kajosaari et al. 
2005a). Genetic association data have suggested that repaglinide is a substrate for 
OATP1B1 (Niemi et al. 2005b).
In pharmacokinetic interaction studies in humans, CYP3A4 inhibition (by 
ketoconazole, itraconazole, clarithromycin and telithromycin) has modestly 
(approximately 15-80%) increased the AUC of repaglinide (Niemi et al. 2001a, 
Hatorp et al. 2003, Niemi et al. 2003c, Kajosaari et al. 2006). Cyclosporine, 
an inhibitor of CYP3A4 and OATP1B1, has raised the AUC of repaglinide by 
2.4-fold (Kajosaari et al. 2005b). Th e CYP2C8-inhibiting antibacterial agent 
trimethoprim has raised the AUC of repaglinide by 60% (Niemi et al. 2004b). 
Gemfi brozil, an inhibitor of CYP2C8 and OATP1B1, has increased the AUC of 
repaglinide by about 8-fold, and the combination of itraconazole and gemfi brozil 
has increased the AUC of repaglinide by about 20-fold, greatly enhancing and 
prolonging its blood glucose lowering eff ect (Niemi et al. 2003c). Th us, both 
CYP2C8 and CYP3A4 seem to metabolise repaglinide in vivo, and the simultaneous 
inhibition of both metabolic routes (and OATP1B1) results in the greatest 
interaction. CYP enzyme induction by rifampicin has considerably decreased the 
plasma concentrations of repaglinide (Niemi et al. 2000).
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AIMS OF THE STUDY
Pioglitazone has been reported to be extensively metabolised by mainly CYP2C8, 
CYP2C9 and CYP3A4 in vitro. However, the information is partly discrepant and 
based on unpublished data. Before this study, no controlled studies were available 
concerning the eff ects of CYP enzyme inducers or CYP2C8 inhibitors on pioglitazone 
pharmacokinetics. Th e aim of this work was to investigate the potential pharmacokinetic 
drug-drug interactions related to the use of pioglitazone.
Specifi c aims of the studies were:
I To identify the CYP enzymes that metabolise pioglitazone and to 
examine the eff ects of the CYP2C8 inhibitors montelukast, zafi rlukast, 
trimethoprim and gemfi brozil on pioglitazone metabolism in vitro.
II To investigate the eff ects of the CYP2C8 inhibitor gemfi brozil, the 
CYP3A4 inhibitor itraconazole and their combination on the 
pharmacokinetics of pioglitazone to determine the role of these 
enzymes in the fate of pioglitazone in humans.
III To investigate the eff ects of montelukast and zafi rlukast, potent 
inhibitors of CYP2C8 and pioglitazone metabolism in vitro, on the 
pharmacokinetics of pioglitazone in humans.
IV To investigate the eff ect of the potent CYP enzyme inducer rifampicin 
on the pharmacokinetics of pioglitazone in humans.
V To investigate the eff ect of pioglitazone on the pharmacokinetics and 
pharmacodynamics of repaglinide in order to evaluate the potential of 
pioglitazone to interact with a CYP2C8 and CYP3A4 substrate drug in 
humans.
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MATERIALS AND METHODS
1. In vitro study (Study I)
1.1. Microsomes and recombinant CYP enzymes
Human liver microsomes (HLM), representing a pool from 46 individuals, mostly of 
Caucasian origin, were purchased from Gentest Corporation (Woburn, MA, USA). 
Human liver tissue had been collected in accordance with all pertinent regulations, 
and permission from the donors’ families had been obtained prior to organ 
collection. Th e organ collection procedures had been reviewed and approved by 
the respective institutional Human Subjects Committee. Human recombinant CYP 
isoforms (SupersomesTM) from baculovirus-infected insect cells expressing cDNA 
encoding human CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
CYP3A4 and CYP3A5, and insect cell control supersomes lacking CYP content, 
were purchased from Gentest Corporation. HLM and recombinant CYP enzymes 
were stored at -70°C, thawed in a water bath and placed on ice before addition into 
the incubation mixture.
1.2. Incubation conditions
Th e incubations were carried out in 0.1 M sodium phosphate buff er (pH 7.4), 
containing 5.0 mM MgCl2, 1 μM pioglitazone, 1.0 mM β-NADPH and 0.3 mg/ml 
microsomal protein or 20 pmol/ml recombinant CYP. Th e initial concentration of 
pioglitazone (1 µM, i.e. 357 ng/ml) was roughly at the same level as the therapeutically 
relevant plasma Cmax in humans (Eckland and Danhof 2000). HLM concentration 
was chosen on the basis of preliminary experiments. Pioglitazone, solvent with or 
without inhibitor, buff er and HLM or recombinant enzymes were premixed, and 
incubations were commenced by the addition of β-NADPH. Zafi rlukast stock solution 
was prepared in acetonitrile, the stock solutions of other drugs were prepared in 
methanol. Final solvent concentration did not exceed 1% and was equal in all control 
incubations. All incubations were conducted in duplicate at 37°C in a shaking water 
bath and terminated by removing an aliquot (0.5 ml), adding it to 100 μl of perchloric 
acid (70%) and cooling on ice. Th e mean values of the duplicates were used in the 
calculations.
1.3. Pioglitazone metabolism and inhibition experiments
First, the metabolism of pioglitazone in HLM was studied by measuring the depletion 
of parent pioglitazone and the formation of its metabolites as a function of time. Th e 
depletion of unchanged pioglitazone at 60 minutes and the formation of the primary 
main metabolite M-IV at 8 minutes aft er incubation with HLM or recombinant 
CYP isoforms were then used as the measure of pioglitazone metabolism in further 
experiments.
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To examine the eff ects of diff erent CYP inhibitors on the metabolism of pioglitazone 
in HLM, montelukast (1 μM) and trimethoprim (100 μM) were used as inhibitors 
of CYP2C8, gemfi brozil (100 μM) as an inhibitor of both CYP2C9 and CYP2C8, 
ketoconazole (1 μM), itraconazole (3 μM) and troleandomycin (100 μM) as inhibitors 
of CYP3A4, sulfaphenazole (10 μM) as an inhibitor of CYP2C9, omeprazole (10 μM) 
as an inhibitor of CYP2C19, furafylline (20 μM) as an inhibitor of CYP1A2, quinidine 
(10 μM) as an inhibitor of CYP2D6, diethyldithiocarbamate (DDC; 100 μM) as an 
inhibitor of CYP2E1, clopidogrel (1 μM) as an inhibitor of CYP2B6 and rifampicin 
(100 μM) as an inhibitor of CYP2C8 and CYP3A4 (Baldwin et al. 1995, Newton et al. 
1995, Bourrié  et al. 1996, Ko et al. 1997, Eagling et al. 1998, Wen et al. 2001, Wang et al. 
2002, Wen et al. 2002, Isoherranen et al. 2004, Richter et al. 2004, Kajosaari et al. 2005a, 
Walsky et al. 2005b). Th e fi nal concentration of each inhibitor was chosen according 
to the aforementioned publications. Mechanism-based inhibitors troleandomycin, 
furafylline, DDC and clopidogrel were pre-incubated with HLM for 15 minutes, aft er 
which pioglitazone was added.
Th e metabolism of pioglitazone by CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, CYP3A4 and CYP3A5 was screened by using 20 pmol/ml 
recombinant CYP enzymes and the same incubation conditions as described above. 
Th e metabolism of pioglitazone by insect cell control supersomes was also studied.
1.4. Determination of IC50 values of CYP2C8 inhibitors
As the metabolism of pioglitazone was predominantly CYP2C8 mediated, the eff ects 
of CYP2C8 inhibitors were studied in more detail. Pioglitazone was co-incubated with 
montelukast (0-3 µM), zafi rlukast (0-10 µM), trimethoprim (0-240 µM) and gemfi brozil 
(0-180 µM) using HLM and the previously described incubation conditions. Th e 
depletion rate of unchanged pioglitazone and the formation rate of the metabolite 
M-IV were calculated. Th e inhibitor concentrations producing a 50% decrease in the 
original enzyme activity (IC50) were determined using non-linear regression analysis 
with the program FigP (version 6.0, Biosoft , Cambridge, UK).
1.5. Determination of pioglitazone and metabolite concentrations
Aft er addition of internal standard (rosiglitazone 3 µg/ml in methanol-water 20:80 v/v), 
the incubations aliquots were applied to solid-phase extraction cartridges conditioned 
with methanol (1 ml) and water (1 ml). Th e cartridges were washed with 1 ml of 100 mM 
hydrochloric acid and 1 ml of 70% methanol, and the analytes were eluted with 1 ml of 
2% ammonium hydroxide in methanol. Th e eluent was evaporated to dryness under 
nitrogen stream (50°C), and the residues were dissolved in 100 µl of acetonitrile-water 
(45:55 v/v) and transferred into autosampler vials.
Th e concentrations of pioglitazone and its metabolites were measured by use of 
a PE SCIEX API 2000 liquid chromatography-tandem mass spectrometry (LC-
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MS-MS) system (Sciex Division of MDS Inc., Toronto, Ontario, Canada) (Lin et al. 
2003). Chromatography was performed on an XTerra RP C18 column (3.9x100 
mm; Waters, Milford, MA, USA) using a mobile-phase gradient consisting of 10 
mM ammonium acetate (pH 9.5). Th e mass spectrometer was operated in positive 
atmospheric pressure chemical ionization mode with selected reaction monitoring. 
Th e ion transitions monitored were mass-to-charge ratio (m/z) 357 to m/z 134 for 
pioglitazone, m/z 371 to m/z 148 for M-III, m/z 373 to m/z 150 for M-IV, m/z 387 
to m/z 164 for M-V, m/z 389 to m/z 166 for M-XI and m/z 358 to m/z 135 
for rosiglitazone. Th ese transitions represent the product ions of the [M+H]+ ions. 
Th e limit of quantifi cation for pioglitazone was 0.3 nM, and the coeffi  cient of variation 
(CV) was 9.1% at 0.045 µM, 4.9% at 0.6 µM and 4.4% at 2.25 µM (n=12). Because 
authentic standards for the metabolites were not available, their quantities are given in 
arbitrary units (U/ml) relative to the ratio of the peak height of the metabolite to the 
peak height of the internal standard. A signal-to-noise ratio of 10:1 was used as the 
limit of detection for the metabolites.
2. In vivo studies (Studies II-V)
Th e studies were carried out at the Department of Clinical Pharmacology, University 
of Helsinki. Th e study protocols were approved according to current regulations by the 
Ethics Committee for Studies in Healthy Subjects and Primary Care of the Helsinki and 
Uusimaa Hospital District and by the Finnish National Agency for Medicines. Before 
entering the studies, the volunteers had received both oral and written information 
and had given a written informed consent. 
2.1. Subjects
A total of 40 (28 male, 12 female) healthy volunteers participated in the studies (Table 2). 
Th e subjects were ascertained to be healthy by medical history, clinical examination and 
routine laboratory tests. None of the subjects was using continuous medication or oral 
contraceptives or was a frequent smoker. Female subjects gave a negative pregnancy 
test before entering the studies. Th e use of grapefruit juice or any pharmaceuticals 
was prohibited 1 week prior to each study. Participation in any other trial and blood 
donation within 1-2 months before or aft er the studies were also prohibited.
Table 2. Characteristics of the subjects.
Study Subjects
n (male/female)
Age (y) Weight (kg) Body mass 
index (kg/m2)
II 12 (9/3) 23 ± 3 70 ± 9 22 ± 2
III 12 (8/4) 24 ± 2 72 ± 12 23 ± 2
IV 10 (7/3) 23 ± 1 69 ± 8 22 ± 2
V 12 (10/2) 23 ± 2 71 ± 12 23 ± 4
Age, weight and body mass index are mean ± SD (standard deviation).
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2.2. Study design
All four studies were of randomised, placebo-controlled crossover design. Details of 
the studies are given in Table 3.
Table 3. Structure of the studies.
Study Pretreatment medication and dose Duration of 
pretreatment
Wash-out 
period 
(weeks)
Study drug and dose
II Gemfi brozil 600 mg x 2
Itraconazole 100 mg x 2 
   (fi rst dose 200 mg)
Gemfi brozil and itraconazole
Placebo x 2
4 days 
at 08:00 and 
20:00
4 Pioglitazone 15 mg 
on day 3 at 09:00
III Montelukast 10 mg x 1 and 
placebo x 1
Zafi rlukast 20 mg x 2
Placebo x 2
6 days
at 09:00 (day 3, 
08:00) and 21:00 
3 Pioglitazone 15 mg 
on day 3 at 09:00
IV Rifampicin 600 mg x 1
Placebo x 1
6 days 
at 20:00
4 Pioglitazone 30 mg 
on day 6 at 09:00
V Pioglitazone 30 mg x 1
Placebo x 1
5 days
at 08:00
4 Repaglinide 0.25 mg
on day 5 at 09:00
Th e pretreatment medication and placebos were supplied, packed and labelled 
according to a randomisation list for each subject by the Helsinki University Central 
Hospital (HUCH) Pharmacy. Th e study drugs (pioglitazone and repaglinide) were 
also supplied by the pharmacy. Repaglinide tablets (0.5 mg) were halved and weighed 
by the investigators. Th e doses of pretreatment drugs and pioglitazone were chosen to 
refl ect current use. A small dose of repaglinide was used for safety reasons.
Th e study drugs were given orally with 150 ml of water aft er an overnight fast at 09:00. 
In Studies II-IV, the subjects received a standard warm meal 3 hours, and light meals 
7 and 11 hours aft er pioglitazone intake. In Study V, each subject received a standardised 
breakfast (eaten in 10 minutes) precisely 15 minutes aft er the administration of 
repaglinide, 2 standardised snacks (eaten in 5 minutes) aft er 1 and 2 hours, a standard 
warm meal aft er 3 and 7 hours and a standard light meal aft er 11 hours. Food intake 
was identical in the diff erent study phases. During the study days, the subjects were 
under direct medical supervision. During the days of repaglinide administration, blood 
glucose levels were monitored throughout the day. Additional carbohydrates, glucose 
solution for intravenous use and glucagon for intramuscular use were available, but 
they were not needed.
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2.3. Blood and urine sampling
On the days of administration of the study drugs, a forearm vein of each subject was 
cannulated for blood sampling. In Studies II-IV, timed blood samples were drawn 
before the administration of pioglitazone and at 1, 2, 3, 4, 5, 7, 9, 12, 24 and 48 hours 
aft er (also at 72 and 96 hours in Study III). In Study V, the blood samples were collected 
before the administration of repaglinide and 20, 40, 60, 80 and 100 minutes and 2, 2½, 3, 
4, 5, 7, 9 and 12 hours later. Blood samples (10 ml) were collected into tubes containing 
ethylenediaminetetra-acetic acid (EDTA). In Study V, blood glucose concentrations 
were measured immediately aft er each blood sampling by the glucose oxidase method 
(Precision G Blood Glucose Testing System, Medisense, Bedford, MA, USA). Plasma 
was separated by centrifugation within 30 minutes and stored at –70°C until analysis. 
In Studies II and IV, urine was collected cumulatively in fractions of 0 to 12, 12 to 24 and 
24 to 48 hours aft er the administration of pioglitazone. Aft er each collection period, the 
volume of urine was measured and an aliquot was stored at –70°C until analysis.
2.4. Determination of plasma and urine drug concentrations
2.4.1. Pioglitazone and pioglitazone metabolites
Th e concentrations of pioglitazone and its metabolites were measured by using PE 
SCIEX API 3000 and PE SCIEX API 2000 (Study IV, urine drug concentrations) liquid 
chromatography-tandem mass spectrometry systems (Sciex Division of MDS Inc., 
Toronto, Ontario, Canada) (Lin et al. 2003). Chromatography was performed on XTerra 
RP C18 column (3.9x100 mm; Waters, Milford, MA, USA) using gradient elution. 
Th e mobile phase consisted of 10 mM ammonium acetate (pH 9.0-9.5, adjusted with 
25% ammonia solution) and acetonitrile. Rosiglitazone served as an internal standard. 
Th e mass spectrometers were operated in the atmospheric pressure chemical ionization 
with positive ion detection mode. Th e ion transitions monitored were mass-to-charge 
ratio (m/z) 357 to m/z 134 for pioglitazone, m/z 371 to m/z 148 for M-III, m/z 373 to 
m/z 150 for M-IV, m/z 387 to m/z 164 for M-V and m/z 389 to m/z 166 for a previously 
unrecognised metabolite designated M-XI and m/z 358 to m/z 135 for rosiglitazone. 
Th ese transitions represent the product ions of the [M+H]+ ions. In Study II, the limit 
of quantifi cation for pioglitazone in plasma was 0.5 ng/ml and the day-to-day CV was 
3.9% at 20 ng/ml, 1.8% at 200 ng/ml and 2.9% at 2000 ng/ml (n=12). In Study III, the 
limit of quantifi cation for pioglitazone was 0.1 ng/ml and the day-to-day CV was 5.7% 
at 0.5 ng/ml (n=6), 9.0% at 20 ng/ml (n=6), 3.0% at 200 ng/ml (n=6) and 11.9% at 
2000 ng/ml (n=5). In Study IV, the limit of quantifi cation for pioglitazone in plasma 
was 0.1 ng/ml and the day-to-day CV was 3.6% at 20 ng/ml, 3.3% at 200 ng/ml and 
6.3% at 2000 ng/ml (n=5). A signal-to-noise ratio of 10:1 was used as the limit of 
detection for pioglitazone metabolites, and their quantities are given in arbitrary units 
(U) relative to the ratio of the peak height of the metabolite to the peak height of the 
internal standard.
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2.4.2. Gemﬁ brozil, itraconazole and hydroxyitraconazole (Study II)
Plasma gemfi brozil concentrations were determined by high-performance liquid 
chromatography (HPLC) with ultraviolet detection and ibuprofen as an internal standard 
(Hengy and Kölle 1985). Day-to-day CV was below 15% at relevant concentrations. 
Plasma itraconazole and hydroxyitraconazole were also determined by HPLC with 
CVs below 4% and 6%, respectively, at relevant concentrations (Remmel et al. 1988, 
Allenmark et al. 1990).
2.4.3. Montelukast and zaﬁ rlukast (Study III)
Th e concentrations of montelukast and zafi rlukast were measured from samples taken 
before and at 1, 2, 4 and 12 hours aft er pioglitazone administration by HPLC with 
fl uorescence detection (Bui et al. 1997, Radhakrishna et al. 2003). Day-to-day CV was 
below 18% for montelukast and below 10% for zafi rlukast at relevant concentrations.
2.4.4. Repaglinide (Study V)
Plasma repaglinide concentrations were quantifi ed by using a PE SCIEX API 3000 
LC-MS-MS system. Reversed-phase chromatographic separation was achieved on 
a Symmetry C8 column (150x2.1 mm inner diameter, 3.5 µm particle size; Waters, 
Milford, MA, USA) using gradient elution. Th e mobile phase consisted of 10 mM 
ammonium formate (pH 4.0, adjusted with 99% formic acid) and acetonitrile. 
Th e mass spectrometer was operated in positive TurboIonSpray mode, and the samples 
were analysed via selected reaction monitoring employing the transition of the [M+H]+ 
precursor ion to product ion for repaglinide. Th e ion transitions monitored for 
repaglinide were m/z 453 to m/z 230. Th e limit of quantifi cation was 0.02 ng/ml, and 
day-to-day CV was 12.6% at 0.1 ng/ml and 5.4% at 2.0 ng/ml (n=7).
2.5. Pharmacokinetic calculations
Th e pharmacokinetics of the study drugs (pioglitazone, pioglitazone metabolites 
and repaglinide) were characterised by peak concentration in plasma (Cmax), time to 
Cmax (tmax), elimination half-life (t½), areas under the plasma concentration-time curve 
from time 0 to 48 hours [AUC(0-48); Studies II and IV] or infi nity [AUC(0-∞)] and 
concentration measured at 48 hours (C48; Studies II and IV). Th e Cmax and tmax values 
were taken directly from the original data. For each subject, the terminal log-linear 
part of the concentration-time curve was identifi ed visually, and the elimination rate 
constant (ke) was determined by linear regression analysis of the log-linear part of the 
concentration-time curve. Th e t½ was calculated by the equation t½ = ln2/ke. Th e AUC 
values were calculated by the linear trapezoidal rule for the rising phase and the log-
linear trapezoidal rule for the descending phase, with extrapolation to infi nity, when 
appropriate, by division of the last measured concentration by ke. Th e pharmacokinetic 
calculations were performed with an MK-model, version 5.0 (Biosoft , Cambridge, UK). 
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In Study II, the t½ and the AUC(0-∞) of the metabolites M-III and M-IV could not 
be determined reliably during the gemfi brozil and gemfi brozil-itraconazole phases 
because the Cmax of the metabolites was reached very late in most subjects due to the 
inhibition eff ect. Gemfi brozil, itraconazole and hydroxyitraconazole pharmacokinetics 
were characterised by Cmax, concentration measured 48 hours aft er pioglitazone dosing 
(C48), AUC from 08:00 (on day 3) to 9 hours aft er pioglitazone dosing [AUC(0-10)] 
and AUC to 49 hours [AUC(0-49)].
In Study IV, the plasma concentrations of parent pioglitazone seemed to decline 
biphasically, particularly during rifampicin treatment. Th erefore, for the fi rst dominant 
elimination phase (the phase contributing most to the AUC), the elimination rate 
constant (ke) was determined by linear regression analysis using the fi rst log-linear 
phase of the descending plasma concentration curve, and for the slow elimination 
phase, starting between 9 and 12 hours, a terminal elimination rate constant (ke,terminal) 
was determined by using the log-linear terminal part of the plasma concentration-
time curve. Th e dominant and terminal half-lives for pioglitazone were calculated 
from the equations t½ = ln2/ke and t½,terminal = ln2/ke,terminal. Th e AUC for pioglitazone 
was calculated by the linear trapezoidal rule for the rising phase and the log-linear 
trapezoidal rule for the descending phase, with extrapolation to infi nity by division 
of the last measured concentration by ke,terminal. Th e plasma concentrations of the 
metabolites declined monophasically. An apparent formation rate constant (kf) was 
calculated for the primary metabolite M-IV by the method of residuals from the 
ascending part of the metabolite concentration-time curve.
In Study V, the pharmacokinetics of parent pioglitazone were characterised by 
Cmax and AUC from 08:00 (on day 5) to 12 hours aft er repaglinide dosing [AUC(0-13)]. 
In Studies II and IV, the cumulative 48-hour excretion [Ae(0-48)] of pioglitazone (ng) 
and its metabolites (U) into urine were determined, and the renal clearance (Clrenal) of 
pioglitazone was calculated from the expression Ae(0-48)/AUC(0-48).
2.6. Pharmacodynamic measurements 
In Study V, the pharmacodynamic eff ects of repaglinide were characterised by the 
maximum increase and maximum decrease in blood glucose concentration and by 
mean change in blood glucose concentration (from 0 to 3 hours, 0 to 7 hours and 0 to 
12 hours) aft er repaglinide intake. Th e mean change was calculated by dividing the net 
area under the blood glucose concentration-time curve (from 0 to 3 hours, 0 to 7 hours 
and 0 to 12 hours) by the corresponding time interval.
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2.7. In vitro-in vivo interaction predictions
In Study V, the eff ect of pioglitazone on the AUC of a CYP2C8 substrate was estimated 
on the basis of pioglitazone’s previously reported Ki value for CYP2C8 using the 
following equation:
  
,where  [I]in vivo = inhibitor concentration available to the enzyme in vivo
  fm = fraction of the substrate metabolised via the inhibited enzyme 
Th e [I]in vivo values were calculated using following equations:
Systemic total Cmax:   [I]in vivo = Cmax 
Systemic free Cmax:   [I]in vivo = fu · Cmax
Estimated total portal Cmax:  [I]in vivo = Cmax + ka · Fa · D / Qh
Estimated free portal Cmax:  [I]in vivo = fu · (Cmax + ka · Fa · D / Qh)
,where  fu = unbound fraction
  ka = absorption rate constant
  Fa = oral bioavailability
  D = dose
  Qh = hepatic blood fl ow
2.8. Statistical analysis
In Studies II and III, statistical comparisons among the phases were made with 
repeated-measures ANOVA, with treatment sequence as a factor, and a posteriori 
testing was conducted with paired t-test with the Bonferroni correction. Th e tmax values 
were compared with Friedman’s two-way ANOVA followed by the Wilcoxon signed-
rank test with the Bonferroni correction. In Studies IV and V, the pharmacokinetic 
and pharmacodynamic variables between the two phases were compared by using 
a paired t-test, or in the case of tmax, by the Wilcoxon signed-rank test. Th e level of 
statistical signifi cance was P < 0.05 in all studies. Pharmacokinetic variables were log-
transformed before the statistical analysis, when appropriate. In Study II, the Pearson 
correlation coeffi  cient was used to investigate the possible relationship between the 
concentrations of gemfi brozil and the extent of the interaction. In Study IV, 95% 
confi dence intervals were calculated on the mean diff erences between the placebo 
and rifampicin phases for all pharmacokinetic variables, except tmax. All the data were 
analysed with the statistical program Systat for Windows, version 6.0.1 (SPSS Inc., 
Chigago, IL, USA).
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RESULTS
1. Metabolism of pioglitazone in vitro (Study I)
Incubation of pioglitazone (1 µM) with HLM resulted in time- and NADPH-dependent 
substrate consumption and metabolite formation. Two major metabolites, M-IV and 
M-III, were found. Th e metabolite M-XI was also detectable, but its formation was 
very low compared with that of M-IV. In addition, trace amounts of the metabolite 
M-V were observed. Th e decline in pioglitazone concentration was log-linear for 
60 minutes, and the formation of the major primary metabolite M-IV was linear for at 
least 8 minutes.  
Th e eff ects of chemical CYP inhibitors on pioglitazone depletion and M-IV formation 
in HLM are shown in Table 4. Montelukast and trimethoprim (selective CYP2C8 
inhibitors), gemfi brozil (inhibits both CYP2C8 and CYP2C9), ketoconazole, 
itraconazole and troleandomycin (CYP3A4 inhibitors), rifampicin (inhibits both 
CYP2C8 and CYP3A4) and DDC markedly inhibited the metabolism of pioglitazone. 
Montelukast (1 µM) was the most potent inhibitor, with 63% inhibition of pioglitazone 
metabolism and 85% inhibition of M-IV formation.
Table 4. Percentage of inhibition of pioglitazone (1 µM) metabolism by inhibitors 
of a range of CYP isoforms in HLM and percentage of pioglitazone depletion by 
diff erent recombinant CYP enzymes.
% inhibited % pioglitazone
Target CYP Inhibitor
Pioglitazone 
depletion
M-IV
formation
metabolised by 
recombinant CYP
CYP2C8 Montelukast 1 µM 63 85 56
Gemfi brozil 100 µM 35 71
Trimethoprim 100 µM 37 66
CYP3A4 Ketoconazole 1 µM 37 55 37
Itraconazole 3 µM 28 46
Troleandomycin 100 µM 17 35
CYP2C8 and 3A4 Rifampicin 100 µM 14 51
CYP1A2 Furafylline 20 µM 4 0 15
CYP2C9 Sulfaphenazole 10 µM 5 13 3
CYP2C19 Omeprazole 10 µM 10 15 10
CYP2B6 Clopidogrel 1 µM 10 18 0
CYP2D6 Quinidine 10 µM 6 24 3
CYP2E1 DDC 100 µM 25 33 1
CYP3A5 - - - 15
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Recombinant CYP2C8 and CYP3A4 decreased the concentrations of pioglitazone by 
56% and 37%, respectively (Table 4). When incubated with recombinant CYP3A5, 
CYP1A2 or CYP2C19, 10-15% of pioglitazone was metabolised. Control supersomes 
did not metabolise pioglitazone. Th e formation rate of metabolite M-IV was highest 
in incubations with CYP2C8, while CYP3A4, CYP3A5 and CYP2C19 catalysed the 
formation of M-IV at a low rate. Metabolite M-III was also formed by incubation of 
pioglitazone with CYP2C8, CYP2C19 and CYP1A2.
All the CYP2C8 inhibitors used (montelukast, zafi rlukast, trimethoprim and 
gemfi brozil) concentration-dependently inhibited pioglitazone metabolism in HLM. 
Th eir IC50 values are shown in Table 5. 
Table 5. IC50 values of the studied CYP2C8 inhibitors for 
metabolism of pioglitazone (1 µM) in HLM.
IC50 values (µM)
Inhibitor Pioglitazone depletion M-IV formation
Montelukast 0.51 0.18
Zafi rlukast 1.0 0.78
Trimethoprim 99 71
Gemfi brozil 98 59
2. Eﬀ ects of gemﬁ brozil and itraconazole on pioglitazone (Study II)
2.1. Pioglitazone pharmacokinetics in plasma
Gemfi brozil raised the mean AUC(0-∞) of unchanged pioglitazone by 3.2-fold 
(P < 0.001) and prolonged its mean t½ considerably, from 8.3 to 22.7 hours (P < 0.001), 
compared with placebo (Figure 2). An increase in the AUC(0-∞) (range 2.3-fold to 
6.5-fold) and t½ was observed in every subject. Gemfi brozil had no eff ect on the Cmax or 
tmax of pioglitazone. 
Itraconazole alone had no signifi cant eff ect on any of the pharmacokinetic variables 
of pioglitazone. Th e gemfi brozil-itraconazole combination raised the AUC(0-∞) of 
pioglitazone by 3.9-fold (P < 0.001) and prolonged the t½ from 8.3 to 40 hours (P < 
0.001), but had no statistically signifi cant eff ect on the Cmax of pioglitazone, compared 
with placebo. No signifi cant diff erences in pioglitazone pharmacokinetics were 
observed between the gemfi brozil and gemfi brozil-itraconazole phases.
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RESULTS
Figure 2. Eff ect of gemfi brozil (Gem), itraconazole (Itr), both gemfi brozil and 
itraconazole (G+I), montelukast (Mon) and zafi rlukast (Zaf) on pharmacokinetics 
of pioglitazone (15 mg) in Studies II and III. Ratios of mean values and range of 
ratios in individual subjects of AUC(0-∞), t½ and Cmax of unchanged pioglitazone 
during the inhibitor phases to those during the placebo phase (control) are 
presented. * P < 0.001 versus control.
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2.2. Pioglitazone metabolites in plasma
Compared with placebo, gemfi brozil reduced the Cmax of the active metabolites M-IV 
and M-III by 49% (P < 0.001) and 45% (P < 0.001) and the AUC(0-48) by 45% 
(P < 0.001) and 42% (P < 0.05), respectively, but the total AUCs of the metabolites were 
reduced less or not at all. Gemfi brozil reduced the M-IV/pioglitazone AUC(0-48) ratio 
by 78% (P < 0.001) and the M-III/pioglitazone AUC(0-48) ratio by 77% (P < 0.001). 
Itraconazole alone did not change the plasma concentration of M-IV or M-III, and the 
gemfi brozil-itraconazole combination caused similar changes in the pharmacokinetic 
variables of the metabolites as gemfi brozil alone. 
2.3. Excretion of pioglitazone and its metabolites in urine
Compared with the placebo phase, gemfi brozil alone increased the amount of 
unchanged pioglitazone excreted in urine within 48 hours by 2.5-fold (P < 0.001) 
and reduced the urinary excretion of M-IV and M-III by 58% (P < 0.001) and 43% 
(P = 0.09), respectively. Th e Ae(0-48) ratios of M-IV and M-III to pioglitazone 
were reduced by 82% (P < 0.001) and 78% (P < 0.001), respectively, by gemfi brozil. 
Itraconazole had no signifi cant eff ect on the excretion of pioglitazone. Gemfi brozil and 
itraconazole did not aff ect the renal clearance of pioglitazone.
Th e excretion of M-V in urine was reduced only insignifi cantly by gemfi brozil alone 
or itraconazole alone, but during the gemfi brozil-itraconazole phase, the 48-hour 
excretion of M-V was reduced by 46% (P < 0.05) compared with placebo. 
Th e Ae(0-48) ratio of M-V to pioglitazone was reduced non-signifi cantly (24%; 
P > 0.05) by itraconazole, by 54% (P < 0.05) by gemfi brozil and by 76% (P < 0.001) 
by the gemfi brozil-itraconazole combination compared with placebo. 
2.4. Gemﬁ brozil, itraconazole and hydroxyitraconazole concentrations
Th e plasma concentrations of itraconazole and hydroxyitraconazole were markedly 
lower during the gemfi brozil-itraconazole phase than during the itraconazole phase. 
Gemfi brozil reduced the mean Cmax and AUC(0-49) of itraconazole by 48% and 
46%, respectively, and those of hydroxyitraconazole by 40% and 46%, respectively 
(P < 0.001). Gemfi brozil pharmacokinetics were not changed by itraconazole. Th e 
correlation between the AUC(0-10) of gemfi brozil and the increase in the AUC(0-∞) 
of pioglitazone was not statistically signifi cant (r = 0.245; P = 0.43).
3. Eﬀ ects of montelukast and zaﬁ rlukast on pioglitazone (Study III)
3.1. Pioglitazone pharmacokinetics in plasma
Montelukast and zafi rlukast had no signifi cant eff ects on any of the pharmacokinetic 
variables of parent pioglitazone (Figure 2). In the montelukast and zafi rlukast phases, 
RESULTS
Jaakkola_Tiina_vaitos.indd   42 17.7.2007   21:12:04
43
the mean AUC(0-∞) values of unchanged pioglitazone were 101% (range 71-143%) 
and 103% (range 78-146%) of the control, respectively. Th e t½ values of pioglitazone 
were 7.6 ± 1.7, 7.5 ± 1.5 and 7.9 ± 1.7 hours in the placebo, montelukast and zafi rlukast 
phases, respectively. 
3.2. Pioglitazone metabolites in plasma
Montelukast and zafi rlukast had no eff ect on the pharmacokinetics of the 
pioglitazone metabolites M-IV, M-III, M-V or M-XI. 
3.3. Montelukast and zaﬁ rlukast concentrations
On the study day, the mean Cmax of montelukast and zafi rlukast was 550 ± 210 ng/ml 
(range 220-900 ng/ml) and 300 ± 150 ng/ml (range 160-720 ng/ml), respectively.
4. Eﬀ ect of rifampicin on pioglitazone (Study IV)
4.1. Pioglitazone pharmacokinetics in plasma
Rifampicin reduced the mean total AUC(0-∞) of pioglitazone by 54% (range 
20-66%; P < 0.001) and shortened its dominant elimination t½ from 4.9 to 2.3 hours 
(P < 0.001), compared with placebo (Figure 3). Rifampicin had no signifi cant eff ect 
on the Cmax, tmax or t½,terminal  of pioglitazone.
4.2. Pioglitazone metabolites in plasma
Compared with placebo, rifampicin increased the apparent formation rate (kf) of 
the primary active metabolite M-IV by 131% (P < 0.01). Th e tmax of M-IV and 
M-III was also reached signifi cantly earlier during the rifampicin phase than 
during the placebo phase. In addition, rifampicin reduced the AUC(0-∞) of M-IV 
(by 34%; P < 0.01) and M-III (by 39%; P < 0.01), shortened their t½ (M-IV by 
50%; P < 0.001, and M-III by 55%; P < 0.01) and increased the AUC(0-∞) ratios 
of M-IV and M-III to pioglitazone by 44% (P < 0.01) and 32% (P < 0.01), respectively. 
Th e AUC(0-48) values of the metabolites remained unaff ected. 
4.3. Excretion of pioglitazone and its metabolites in urine
Compared with placebo, rifampicin reduced the Ae(0-48) of unchanged pioglitazone 
by 49% (P < 0.0001) and that of M-V by 43% (P = 0.07), whereas the Ae(0-48) of 
M-IV and M-III remained unchanged. A previously unrecognised metabolite, M-XI, 
tentatively identifi ed as a dihydroxymetabolite, was found in urine during both phases 
(Figure 4). Th e Ae(0-48) of M-XI was increased by 44% (P < 0.05) by rifampicin. 
Rifampicin raised the M-IV/pioglitazone Ae(0-48) ratio by 98% (P < 0.01), the 
M-III/pioglitazone ratio by 95% (P < 0.01) and the M-XI/pioglitazone ratio by 240% 
(P < 0.01). Th e renal clearance of pioglitazone was unaff ected by rifampicin.
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Figure 3. Eff ect of rifampicin on the pharmacokinetics of pioglitazone (30 mg) 
in Study IV. Ratios of mean values and range of ratios in individual subjects of 
AUC(0-∞), t½ and Cmax of unchanged pioglitazone and the active metabolites 
M-IV and M-III during the rifampicin phase to those during the placebo phase 
(control) are presented. * P < 0.001 versus control, ** P < 0.01 versus control.
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5. Eﬀ ect of pioglitazone on repaglinide (Study V)
5.1. Repaglinide pharmacokinetics
Pioglitazone had no signifi cant eff ects on repaglinide pharmacokinetics. In 
the pioglitazone phase, the Cmax and AUC(0-∞) of repaglinide were 100% 
(range 53-157%) and 90% (range 63-120%) of the control values, respectively. 
Th e t½ of repaglinide remained unchanged, about 1 hour in both phases. Th e median 
tmax was 40 minutes (range 20-40 minutes) and 20 minutes (range 20-40 minutes) in 
the placebo and pioglitazone phases, respectively (P < 0.05).
5.2. Eﬀ ect on blood glucose
Pioglitazone did not change the baseline blood glucose concentrations 
(4.6 ± 0.4 mmol/l) compared with the placebo phase (4.5 ± 0.2 mmol/l). 
Th e minimum, maximum and mean change of blood glucose aft er repaglinide 
intake remained unchanged by pioglitazone. None of the subjects had symptomatic 
hypoglycaemia.
5.3. Pioglitazone concentrations
On the study day, the mean Cmax and AUC(0-13) of pioglitazone were 
778 ± 186 ng/ml (range 378-1040 ng/ml) and 5090 ± 1320 ng·h/ml (range 2770-
7250 ng·h/ml), respectively.
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DISCUSSION
1. Methodological considerations
1.1. In vitro study
Th e aim of this study was to determine the contributions of diff erent CYP enzymes to 
the metabolism of pioglitazone and to evaluate the risk of drug interactions in humans 
on the basis of in vitro investigations. Human liver microsomes and recombinant 
CYP enzymes are widely used and well-characterised systems for drug metabolism 
and interaction studies (Pelkonen et al. 2005). HLMs contain all the CYP enzymes 
expressed in the human liver, but diff erent CYP isoforms are present in proportion 
to their representation in individual donor livers. To avoid interindividual variation 
in enzyme activity, pooled HLM (same batch in all experiments) with defi ned 
enzyme activities adequately representing the population average, was used in the 
experiments. Because HLMs contain all CYP enzymes, they are suitable for studying 
mechanism-based inhibitors using preincubation. Studies in HLM were accompanied 
by recombinant CYP enzymes, which are useful in identifying the role of a specifi c 
CYP isoform in the metabolism of a drug or in a particular metabolic pathway.
Because the pharmacological effi  cacy of pioglitazone is due to the net eff ect of 
parent pioglitazone and its major active metabolites M-IV (primary metabolite) and 
M-III (secondary metabolite formed from M-IV) (Eckland and Danhof 2000), both 
the depletion of parent pioglitazone and the formation of primary metabolite M-IV 
were studied aft er incubations with HLM and recombinant CYPs. Th e formation of 
secondary metabolite M-III was also measured, but no IC50 values for M-III were 
calculated because two metabolic steps are involved in its formation. To assure 
constant metabolism, the incubation times used were within the log-linear part of 
pioglitazone depletion and the linear part of M-IV formation, respectively. In addition, 
the concentration of microsomal protein was chosen on the basis of preliminary 
experiments to meet the initial-rate conditions.
Most drugs are poorly soluble in water, and organic solvents are oft en indispensable 
in in vitro experiments. An excess of organic solvents can aff ect enzyme activities of 
diff erent CYP isoforms to a varying degree depending on the solvent used. Methanol 
and acetonitrile were used in this study, and their concentrations in fi nal incubation 
mixtures were kept suffi  ciently low (<1% v/v) to avoid signifi cant CYP enzyme 
inhibition (Chauret et al. 1998, Easterbrook et al. 2001). In addition, the eff ects of 
inhibitors were compared against control incubations (% of control) containing equal 
concentrations of solvents. Other factors in incubation conditions, such as ionic 
strength and pH of the incubation medium, may also infl uence the outcome of in 
vitro studies (Venkatakrishnan et al. 2001). Sodium phosphate buff er (0.1 M) was 
used as the incubation medium, which parallels the pH and ionic strength in hepatic 
cytoplasm in vivo.
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Th e choice of substrate concentration is crucial in in vitro studies, especially when only 
a single substrate concentration is used. For example, for a substrate metabolised by 
multiple CYP enzymes with diff erent affi  nities, use of a high (supratherapeutic) substrate 
concentration will overestimate the contribution of a low-affi  nity isoform, and the 
important contribution of a high-affi  nity isoform (at therapeutic concentrations) may 
be underestimated (Venkatakrishnan et al. 2001). Th e concentration of pioglitazone 
used in this study (1 µM = 357 ng/ml) was chosen to correspond roughly to the peak 
plasma pioglitazone concentration in humans (at a 15-mg dose, about 300-500 ng/
ml)(Eckland and Danhof 2000, Jaakkola et al. 2005). However, plasma concentration of 
a drug does not directly correlate with its concentration at the site of metabolic activity 
in a hepatocyte, and the use of single substrate concentration can be misleading. 
Because reference compounds were not available, the concentrations of the metabolites 
were quantifi ed as arbitrary units only. However, the linearity of the detector response 
of the LC-MS-MS assay could be confi rmed for the metabolites within the relevant 
concentration range by means of a sample dilution. Accordingly, we were able to reliably 
determine the contribution of diff erent CYP enzymes to the formation of metabolites 
as relative changes in metabolite concentrations.
Th e inhibitory potencies of the studied CYP2C8 inhibitors were quantifi ed by 
determination of IC50 values. Th is approach has the advantage of being model 
independent; it does not require a kinetic analysis or a knowledge of the mechanism of 
inhibition (Venkatakrishnan et al. 2001). Th e IC50 values are useful when comparing 
inhibitory potencies of diff erent candidate inhibitors, but they are applicable only to the 
specifi c substrate concentration used (von Moltke et al. 1998). In principle, Ki values 
are needed if in vitro data are used for quantitative in vivo scaling (Venkatakrishnan 
et al. 2001).
Altogether, the use of a single pioglitazone concentration and IC50 values causes 
limitations to the interpretation of the results; this study could have been improved 
by using a range of substrate concentrations, determining apparent kinetic constants 
(Km and Vmax) and determining Ki values for the inhibitors.
1.2. In vivo studies
All four studies were placebo-controlled, randomised, cross-over studies with a wash-
out period of 3-4 weeks. In this design, the subjects serve as their own controls, which 
limits the eff ects of interindividual variation and reduces the number of subjects 
needed. Based on information from previous interaction studies, the number of subjects 
(n=10-12) in each study was estimated to be suffi  cient to detect any clinically signifi cant 
pharmacokinetic interaction (about 30% change in AUC at a statistical signifi cance 
level of P < 0.05) without exposing an unnecessarily large group of healthy volunteers 
to the drugs. Balanced randomisation and adequate wash-out periods were used to 
minimise the risk of possible period eff ects or carry-over eff ects. 
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Th e volunteers fasted overnight before administration of study drugs, and food intake 
during the study days was standardised to reduce possible variation in drug absorption 
and blood glucose concentrations (Study V). Th e timing of administration of the study 
drugs in Studies II, III and V (1 hour aft er pretreatment dose) was chosen to ensure 
adequate absorption of the inhibitor drug before administration of the study drug. 
Rifampicin can act as both an inducer and an inhibitor of CYP2C8 and CYP3A4, and 
as an inhibitor of hepatic uptake transporters (Bidstrup et al. 2004, Kajosaari et al. 
2005a, Lau et al. 2007). Th e decrease in plasma drug concentrations has been smaller 
when rifampicin and the target drug (repaglinide) have been administered at the same 
time (Bidstrup et al. 2004). To avoid this eff ect, rifampicin was administered at 20:00, 
i.e. 13 hours before pioglitazone, in Study IV. 
Signifi cant inhibition of CYP enzymes has been reported to occur immediately aft er 
a single dose of an inhibitor (Lin and Lu 1998). Th e pretreatment period in the studies 
with CYP enzyme inhibitors was 3-5 days, and the concentrations of the inhibitors 
were measured during the study days and ascertained to be at therapeutic levels. It is 
thus unlikely that the interaction observed with gemfi brozil would have been much 
greater aft er a longer pretreatment period. Moreover, the lack of interaction observed 
with montelukast, zafi rlukast and pioglitazone can not be explained by inadequate 
plasma concentrations of the inhibitors. In Study IV, rifampicin was given for 5 days 
before administration of pioglitazone. Compared with enzyme inhibition, enzyme 
induction by rifampicin requires a longer time because new protein must be synthesised. 
Maximal induction of intestinal CYP enzymes and transporters is achieved in about 
1 week, whereas that for hepatic induction can take longer (Lee et al. 1993, Fromm et 
al. 1996, Niemi et al. 2003a). Th us, it is possible that a longer treatment with rifampicin 
would have increased the magnitude of interaction observed with pioglitazone. 
A 5-day pretreatment was chosen on the basis of previous interaction studies and to 
prevent unnecessarily long exposure of healthy volunteers to rifampicin. Because of 
slow elimination of total pioglitazone, blood and urine were sampled for 48-96 hours 
aft er pioglitazone intake in Studies II-IV. To avoid underestimation of the interaction, 
pretreatment drugs were administered also during the sample collection period.
Because healthy subjects are more sensitive to the hypoglycaemic eff ects of repaglinide, 
only a small dose (0.25 mg) of repaglinide was used. Th e pharmacokinetics of 
repaglinide is linear with respect to dose (Hatorp 2002), and it is reasonable to assume 
that the fi ndings can be extrapolated to normal therapeutic doses (0.5-4 mg) of the 
drug. Th e pharmacokinetics of pioglitazone and repaglinide in patients with type 2 
diabetes is similar to that of healthy volunteers (Eckland and Danhof 2000, Hatorp 
2002). Accordingly, the pharmacokinetic interactions can be presumed to be equal in 
both groups.
In Study II, the t½ and AUC(0-∞) of the metabolites M-IV and M-III could not be 
determined reliably during the gemfi brozil and gemfi brozil-itraconazole phases 
because of inhibition of their formation and further elimination by gemfi brozil. 
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Th erefore, a longer sample collection period was used in Study III. Th e concentrations 
of the metabolites of pioglitazone were quantifi ed as arbitrary units only because 
reference compounds were not available. However, the eff ects (or lack thereof) of the 
pretreatment drugs on the metabolite pharmacokinetics could be reliably shown, and 
the results are in good agreement with the pharmacokinetics of parent pioglitazone.
M-V, an inactive polar metabolite, was detected in signifi cant amounts in urine. In 
addition, in Study IV, a previously unrecognised metabolite, M-XI, was found in urine. 
Its mass-to-charge ratio of 389 suggests that the compound is a dihydroxymetabolite, 
formed by further hydroxylation of M-II or M-IV. Th e neutral loss scan of m/z 389 
resulted in the same neutral 223 amu fragment as the parent pioglitazone and its 
other metabolites. During the placebo phase in Study IV, the Ae(0-48) of M-XI was 
approximately one-tenth of that of M-V, which is the main compound in urine. 
Th e plasma concentrations of the metabolites M-V and M-XI seemed to be very low 
compared with those of M-IV in Study III, and their rapid excretion into urine is 
consistent with their polar nature.
In Study IV, the plasma concentrations of unchanged pioglitazone seemed to 
decline biphasically, particularly during induction by rifampicin. Th e majority of 
the elimination of pioglitazone took place during the fi rst phase, and rifampicin 
considerably shortened “the dominant elimination half-life” of pioglitazone associated 
with this phase. However, the long terminal half-life of pioglitazone remained 
unaff ected by rifampicin. Th is could refl ect, for example, a slow release of pioglitazone 
from peripheral tissues, which is not aff ected by induction. An example of this kind 
of situation is the elimination of the aminoglycoside antibiotic gentamycin, which is 
rapidly eliminated from the body during the fi rst phase, before distribution equilibrium 
is slowly achieved during the terminal phase (Tozer and Rowland 2006). According to 
a review of original Japanese studies, biphasic elimination of pioglitazone has been 
observed also previously (Baba 2001), and both one and two elimination half-lives 
have been used in diff erent studies. In the present studies, the use of two diff erent 
models in the pharmacokinetic calculations is somewhat inconsistent, but it does not 
aff ect the magnitude of the observed interactions or the clinical relevance of these 
fi ndings.
2. Metabolism of pioglitazone by CYP enzymes in vitro
Th e results from these in vitro studies clarify the roles of CYP2C8, CYP2C9 and 
CYP3A4 enzymes in the metabolism of pioglitazone. Our fi ndings strongly suggest 
that pioglitazone in vitro is metabolised principally by CYP2C8 and to a lesser extent 
by CYP3A4. Other CYP isoforms seem to play a minor role in the biotransformation 
of pioglitazone.
Th e potent CYP2C8 inhibitors montelukast (highly selective for CYP2C8) and 
zafi rlukast (non-selective) strongly inhibited the depletion of the parent pioglitazone 
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and the formation of the main primary metabolite M-IV, with IC50 values very close 
to their reported values for CYP2C8 (Walsky et al. 2005a, Walsky et al. 2005b). 
Trimethoprim, a moderately potent, selective inhibitor of CYP2C8 (Wen et al. 2002), 
and gemfi brozil, a non-selective CYP2C8 inhibitor (Wen et al. 2001, Wang et al. 
2002), also markedly inhibited pioglitazone metabolism. In addition, in incubations of 
pioglitazone with recombinant CYP2C8, the depletion of pioglitazone was rapid and 
the rate of formation of M-IV was very high, consistent with a major role for CYP2C8 
in the metabolism of pioglitazone. 
Th e potent CYP3A4 inhibitors ketoconazole (1 µM) (Baldwin et al. 1995, Bourrié et 
al. 1996, Eagling et al. 1998), itraconazole (3 µM) (Back and Tjia 1991, Olkkola et al. 
1994, Wang et al. 1999, Isoherranen et al. 2004) and troleandomycin (100 µM) (Newton 
et al. 1995) inhibited pioglitazone metabolism by 17-37%, and the formation of M-
IV by 35-55%. While itraconazole and troleandomycin are more selective inhibitors 
of CYP3A4, ketoconazole inhibits also CYP2C8 activity (by about 30%) at the 
concentration used (Ong et al. 2000). Th us, inhibition of CYP2C8 may partially 
explain the inhibitory eff ect of ketoconazole on the metabolism of pioglitazone. 
With recombinant CYP3A4 and CYP3A5 enzymes, the rate of pioglitazone depletion 
was approximately 70% and 50% of that with CYP2C8, and both these CYP3A 
forms catalysed the formation of M-IV at a low rate compared with CYP2C8. Th is 
fi nding suggests that the CYP3A forms are more important in the formation of 
other pioglitazone metabolites than in the formation of M-IV.
In HLM, inhibitors of CYP2C8 and CYP3A4 had a slightly greater inhibitory eff ect 
on the formation of M-IV than on the depletion of pioglitazone. Th is suggests that 
enzymes other than CYP2C8 and CYP3A4 are involved in the formation of other 
pioglitazone metabolites to a greater extent than in the formation of M-IV. Recombinant 
CYP2C19 catalysed pioglitazone depletion (10% in 60 minutes) and M-IV formation 
to some extent, and the non-selective CYP2C19 inhibitor omeprazole (inhibits also 
CYP2C9 and CYP3A4)(Ko et al. 1997) had a minor eff ect on the metabolism of 
pioglitazone. Recombinant CYP1A2 metabolised pioglitazone by 15% in 60 minutes, 
and catalysed the formation of a low but detectable amount of M-III. However, the 
potent, selective CYP1A2 inhibitor fyrafylline (Eagling et al. 1998) had practically no 
eff ect on pioglitazone elimination or metabolite formation. Th ese fi ndings suggest that 
CYP2C19 and CYP1A2 may be involved, but to a much lesser degree than CYP2C8 
and CYP3A4, in the metabolism of pioglitazone. 
Rifampicin, in addition to its well-known inducing properties, is a competitive inhibitor 
of CYP2C8 and CYP3A4 in vitro (Bidstrup et al. 2004, Kajosaari et al. 2005a). Rifampicin 
(100 µM) inhibited pioglitazone elimination slightly (by 14%), and, particularly, 
the (CYP2C8-mediated) formation of M-IV (by 51%). Th e CYP2E1 inhibitor DDC 
inhibits also CYP2C8 (Ong et al. 2000) and CYP3A4 activities (Eagling et al. 1998), 
which explains our fi nding that DDC inhibited pioglitazone metabolism (by 25%), 
but recombinant CYP2E1 did not metabolise pioglitazone to any appreciable extent. 
DISCUSSION
Jaakkola_Tiina_vaitos.indd   50 17.7.2007   21:12:05
51
Similarly, the CYP2D6 inhibitor quinidine and the CYP2B6 inhibitor clopidogrel 
slightly inhibited pioglitazone metabolism, but the corresponding recombinant CYP 
did not metabolise pioglitazone. Quinidine can slightly inhibit CYP3A4 (Newton et al. 
1995) and clopidogrel inhibits also CYP2C19 (Richter et al. 2004), which could explain 
the fi ndings. CYP2C9 did not metabolise pioglitazone to any appreciable extent, and 
the CYP2C9 inhibitor sulfaphenazole had only a marginal inhibitory eff ect, suggesting 
that CYP2C9 is not signifi cantly involved in pioglitazone elimination. 
Overall, these results are consistent with a major role of CYP2C8 and a less signifi cant 
role of CYP3A4 in the metabolism of pioglitazone. Th e formation of the major 
primary metabolite M-IV also seems to be predominantly catalysed by CYP2C8. 
By contrast, we found no evidence of signifi cant involvement of CYP2C9 in the 
elimination of pioglitazone. CYP2C8 inhibitors montelukast, zafi rlukast, gemfi brozil 
and trimethoprim markedly inhibited pioglitazone metabolism in vitro. Accordingly, 
interaction studies were warranted to evaluate their interaction potency in vivo. 
3. Eﬀ ects of CYP2C8 and CYP3A4 inhibition on pioglitazone 
pharmacokinetics
Inhibition of CYP2C8 by gemfi brozil increased the AUC of pioglitazone over 3-fold 
and considerably prolonged its t½ without aff ecting the Cmax of pioglitazone. Th e Cmax, 
AUC(0-48) and AUC(0-48) ratios of the metabolites M-IV and M-III to pioglitazone 
were lower during the gemfi brozil than during the placebo phase, indicating that 
gemfi brozil inhibits the oxidative metabolism of pioglitazone. Th ese eff ects were seen 
in every subject, although the extent of the interaction varied substantially between 
individuals. Th e potent CYP3A4 inhibitor itraconazole alone had no eff ect on the 
pharmacokinetics of pioglitazone, and the itraconazole-gemfi brozil combination 
caused similar changes in the pharmacokinetics of pioglitazone as gemfi brozil alone. 
In vitro, gemfi brozil is a more potent inhibitor of CYP2C9 than of CYP2C8 (Wen et 
al. 2001, Wang et al. 2002). However, in vivo, gemfi brozil is the most potent CYP2C8 
inhibitor known, and it has markedly (2.2- to 8.1-fold) increased the AUCs of several 
CYP2C8 substrates (Backman et al. 2002, Niemi et al. 2003c, Niemi et al. 2003b, 
Niemi et al. 2006), whereas its eff ects on CYP2C9-mediated metabolism have been 
much smaller or even lacking (Niemi et al. 2001b, Lilja et al. 2005, Niemi et al. 2005a). 
At least part of the in vivo inhibitory eff ect of gemfi brozil on CYP2C8 is caused by 
its glucuronide metabolite, which can probably accommodate the large active site of 
CYP2C8 (Schoch et al. 2004, Shitara et al. 2004, Ogilvie et al. 2006). In our study, 
gemfi brozil considerable increased the AUC and t½ of parent pioglitazone and reduced 
the AUC ratios of both M-IV and M-III to pioglitazone, as well as the urinary excretion 
ratios of both M-IV and M-III to pioglitazone. Th ese results indicate that, also in 
vivo, CYP2C8 has an important role in the total elimination of pioglitazone, and that 
gemfi brozil inhibits the CYP2C8-mediated metabolism of parent pioglitazone and 
the formation of M-IV and M-III. Th e Cmax of pioglitazone remained unaff ected by 
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gemfi brozil. Th us, the eff ect of gemfi brozil on the systemic elimination of pioglitazone 
was considerable, whereas its eff ect on the presystemic metabolism of pioglitazone was 
insignifi cant, consistent with the low hepatic extraction ratio and negligible fi rst-pass 
metabolism of pioglitazone (Eckland and Danhof 2000).
Although the half-lives of the metabolites M-IV and M-III could not be determined 
reliably, the elimination of the metabolites seemed to be considerably slower during 
the gemfi brozil and gemfi brozil-itraconazole phases than during the other two 
phases. Accordingly, the total AUCs of the metabolites were concluded not to be 
markedly reduced by gemfi brozil. Th is fi nding has later been confi rmed by Deng et al. 
in an interaction study using a longer sample collection period; gemfi brozil (600 mg 
twice daily) increased the AUC of parent pioglitazone 3.4-fold and inhibited the further 
elimination of M-IV and M-III (prolonged the half-lives to about 2-fold) without a 
signifi cant change in the total AUCs of the metabolites (Deng et al. 2005). Th us, the 
net eff ect of gemfi brozil is an increase in the total AUC of active compounds, and 
accordingly, enhanced effi  cacy and increased likelihood of concentration-dependent 
adverse eff ects of pioglitazone.
On the other hand, the potent CYP3A4 inhibitor itraconazole had no eff ect on the 
plasma concentrations of pioglitazone or M-IV and M-III or on their excretion 
into urine. Furthermore, itraconazole did not alter the eff ects of gemfi brozil on 
pioglitazone during the gemfi brozil-itraconazole phase. Th is indicates that CYP3A4 
is of minor importance in the total elimination of pioglitazone in vivo, despite its in 
vitro contribution to pioglitazone metabolism. Th e excretion of M-V in urine was 
only slightly and non-signifi cantly reduced by gemfi brozil alone, and by itraconazole 
alone, but it was reduced by 46% during the gemfi brozil-itraconazole phase. Moreover, 
the Ae(0-48) ratio of M-V to pioglitazone was considerably reduced during the 
gemfi brozil-itraconazole phase. Th ese fi ndings suggest that both CYP2C8 and CYP3A4 
may be involved in the formation of M-V in vivo.
According to an update of the Actos prescribing information, ketoconazole has 
increased the AUC of pioglitazone by 34%. In addition to CYP3A4 inhibition, 
ketoconazole can inhibit CYP2C8 (Ong et al. 2000). Th us, inhibition of CYP2C8 most 
likely explains the eff ect of ketoconazole on pioglitazone pharmacokinetics. In line with 
this, ketoconazole has also increased the AUC of the CYP2C8 substrate rosiglitazone 
by 47% (Park et al. 2004b).
During the gemfi brozil-itraconazole phase, the plasma concentrations of both 
itraconazole and hydroxyitraconazole were considerably lower than during the 
itraconazole phase. Th is fi nding, also observed  in two other studies (Niemi et al. 
2003c, Niemi et al. 2006), could be explained by a reduction in the oral bioavailability 
of itraconazole caused by gemfi brozil, or by displacement of itraconazole and 
hydroxyitraconazole from plasma proteins by gemfi brozil, leading to increased 
clearance or volume of distribution.
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4. Eﬀ ects of montelukast and zaﬁ rlukast on pioglitazone 
pharmacokinetics
Th e usual therapeutic doses of montelukast and zafi rlukast had no eff ect on the 
pharmacokinetics of pioglitazone; the Cmax, AUC and t½ of parent pioglitazone and 
those of the metabolites M-IV, M-III, M-V and M-XI in plasma remained essentially 
unchanged. Th is lack of an interaction was somewhat unexpected since especially 
montelukast but also zafi rlukast are potent inhibitors of CYP2C8 (Walsky et al. 2005a, 
Walsky et al. 2005b) and of pioglitazone metabolism in vitro. Th ese fi ndings strongly 
suggest that montelukast and zafi rlukast do not signifi cantly inhibit CYP2C8 enzyme 
in vivo in humans. 
Montelukast is a very potent and selective CYP2C8 inhibitor in vitro (Walsky et al. 
2005b). It has been reported to be more than 99% bound to plasma proteins in vivo 
(Singulair prescribing information). According to previous predictions based on in vitro 
inhibition data and on therapeutic montelukast plasma concentrations, the expected 
magnitude of the drug-drug interaction for a CYP2C8-cleared drug ranges from 
a 2-fold to a 100-fold increase in AUC, depending on whether unbound (assuming 1% 
free fraction) or total montelukast concentration is used in the prediction (Walsky et 
al. 2005b). Unexpectedly, montelukast had no inhibitory eff ect on the elimination of 
pioglitazone in humans. Th e apparent discrepancy between the in vitro data and these 
in vivo fi ndings could be explained by the high plasma protein binding of montelukast 
(>> 99%) limiting the concentration available for CYP2C8 enzyme in the hepatocytes. 
An updated protein binding value of >99.7% for montelukast has been reported 
(Walsky 2006, personal communication), which yields a prediction of <1.3-fold increase 
in the AUC of a CYP2C8 substrate when assuming <0.3% free fraction (Table 6). When 
an assumed 0.1% free fraction is used, montelukast would be estimated to cause only 
a 10% increase in the AUC of a drug cleared by CYP2C8, which is in agreement with 
our in vivo results. Our results are also consistent with recent in vivo fi ndings showing 
that montelukast does not aff ect the pharmacokinetics of the CYP2C8 substrates 
repaglinide and rosiglitazone (Kajosaari et al. 2006, Kim et al. 2006).
Zafi rlukast is also a potent inhibitor of CYP2C8 in vitro (Walsky et al. 2005a). Th e in vitro 
inhibitory potency and the circulating concentrations of zafi rlukast have suggested 
a possibility of some degree of CYP2C8 inhibition in vivo (Walsky et al. 2005a). 
However, also zafi rlukast is extensively (>99%) bound to plasma proteins (Dekhuijzen 
and Koopmans 2002) and if the estimations are based on its unbound concentrations, 
it becomes unlikely that zafi rlukast would cause inhibition of CYP2C8 in vivo 
(Walsky et al. 2005a). Th e lack of eff ect of montelukast and zafi rlukast on pioglitazone 
pharmacokinetics suggests that these drugs have no signifi cant inhibitory potency 
towards CYP2C8 in vivo.
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Table 6. Estimated eff ect of montelukast on the AUC of a drug metabolised solely 
by CYP2C8 in vivo, based on inhibition of CYP2C8 activity by montelukast in vitro.
Magnitude of drug interaction  
(fold increase in exposure)
In vivo inhibitor  
concentration   
available to   
enzyme
Assumed 
unbound 
fraction   
(fu)
Equation used to 
estimate  in vivo inhibitor 
concentration ([I]in vivo) 
available to enzyme
Systemic total Cmax - [I]in vivo = Cmax 99
Systemic free Cmax 1% [I]in vivo = fu ∙ Cmax 2
Systemic free Cmax 0.3% [I]in vivo = fu ∙ Cmax 1.3
Systemic free Cmax 0.1% [I]in vivo = fu ∙ Cmax 1.1
Values used for montelukast include mean peak concentration in plasma in Study III (Cmax) 
(550 ng/ml = 0.9 µmol/l), unbound fraction (fu) (0.1-1%) and inhibition constant (Ki) (0.0092 µmol/l). 
Th e fraction of the aff ected drug metabolised by CYP2C8 (fm) is assumed to be unity in the 
expression.
5. Eﬀ ect of induction on pioglitazone pharmacokinetics
Rifampicin considerably reduced the plasma concentrations of pioglitazone, shortened 
its dominant elimination t½, enhanced the formation of the metabolites M-IV and 
M-III and increased the metabolite/pioglitazone ratios in plasma and urine, indicating 
that rifampicin induced the metabolism of pioglitazone during its elimination 
phase. Th e Cmax of pioglitazone remained unaff ected by rifampicin, consistent with 
the negligible presystemic metabolism of pioglitazone. Rifampicin also shortened 
the t½ of M-IV and M-III, which can be explained by induction of the further 
metabolism of these metabolites. 
Rifampicin is a potent inducer of many enzymes involved in drug metabolism (Niemi 
et al. 2003a). Although rifampicin has its greatest eff ect on the pharmacokinetics of 
CYP3A4 substrate drugs (Backman et al. 1996a, Fromm et al. 1996, Holtbecker et al. 
1996, Villikka et al. 1997, Kyrklund et al. 2000), it can have a considerable eff ect also 
on the pharmacokinetics of drugs metabolised mainly by CYP2C8 (Niemi et al. 2000, 
Niemi et al. 2004a, Park et al. 2004a). Because itraconazole had no signifi cant eff ect on 
the pharmacokinetics of pioglitazone, even when CYP2C8 was inhibited by gemfi brozil, 
induction of CYP3A4 alone can not explain the eff ect of rifampicin on pioglitazone 
pharmacokinetics. Accordingly, rifampicin seems to reduce the plasma concentrations 
of pioglitazone mainly by inducing its CYP2C8-catalysed biotransformation in the 
liver.
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Rifampicin increased the apparent formation rate (kf) of the metabolite M-IV, shortened 
its tmax and increased the M-IV/pioglitazone ratio in plasma and urine, indicating that 
rifampicin enhanced the activity of this metabolic step. Th e further elimination of 
M-IV was also induced by rifampicin, as refl ected by the decrease in the total AUC 
and t½ of M-IV. Th e formation of the secondary metabolite M-III is dependent on the 
formation of its precursor M-IV. Accordingly, the increases in M-III/pioglitazone ratios 
were equal to the increases in M-IV/pioglitazone ratios. Furthermore, the total AUC 
and t½ of M-III were reduced by rifampicin, indicating induction of the elimination of 
M-III as well. Th us, the net eff ect of rifampicin on pioglitazone is a substantial decrease 
in the total AUC of active compounds, which may deteriorate the clinical effi  cacy of 
pioglitazone. 
In addition to the active metabolites, metabolites M-V and M-XI were found in 
urine. Rifampicin showed a tendency to reduce the excretion of M-V into urine, 
which could be explained by reduced plasma concentrations of parent pioglitazone. 
Th e increased excretion of M-XI during the rifampicin phase suggests that its formation 
is inducible.
6. Eﬀ ect of pioglitazone on the CYP2C8 and CYP3A4 substrate 
repaglinide
Administration of pioglitazone did not increase the plasma concentrations of 
repaglinide; the Cmax, AUC and t½ of repaglinide remained unchanged, and only a 
clinically insignifi cant shortening occurred in its tmax. Th e results strongly suggest that 
pioglitazone does not inhibit repaglinide metabolism in vivo, and that its inhibitory 
eff ect on CYP2C8 and CYP3A4 is very weak in humans.
Th e effi  cacy of pioglitazone-repaglinide combination therapy has been compared with 
monotherapy with pioglitazone or repaglinide in type 2 diabetes (Jovanovic et al. 2004). 
Th e eff ect of the combination on glycaemic parameters was much better than that 
of either drug alone or their sum, but the plasma concentrations of pioglitazone and 
repaglinide were not determined. Pioglitazone is a relatively potent in vitro inhibitor 
of CYP2C8 and CYP3A4 (Sahi et al. 2003, Walsky et al. 2005a), and repaglinide is 
susceptible to inhibition of these enzymes (Niemi et al. 2001a, Niemi et al. 2003c, 
Niemi et al. 2004b, Kajosaari et al. 2006). Accordingly, this study was designed to test 
the hypothesis that inhibition of repaglinide metabolism by pioglitazone contributes 
to the synergistic eff ect observed in vivo. 
Calculating the maximum in vivo inhibitory eff ect of pioglitazone, using the Ki of 
1.7 µM for CYP2C8 (Sahi et al. 2003) and estimated total portal Cmax (Eckland and 
Danhof 2000, Walsky et al. 2005a), pioglitazone could cause an almost 3-fold increase 
in the AUC of a drug cleared solely by CYP2C8, and about a 1.5-fold increase in 
the AUC of a drug of which 50% is metabolised by CYP2C8 (such as repaglinide). 
However,  pioglitazone is also highly (97% to over 99%) bound to plasma proteins 
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(Eckland and Danhof 2000, Actos prescribing information) and calculations based 
on the free plasma concentrations, estimating practically no increase in AUC, agree 
well with these in vivo fi ndings.
7. Clinical implications
Many drug-drug interactions are benefi cial, such as when two oral antidiabetics are 
combined to yield synergistic pharmacodynamic effi  cacy. Because of comorbidity 
related to type 2 diabetes, oral antidiabetic drugs oft en need to be used concurrently 
with several other drugs, exposing diabetics also to harmful drug-drug interactions. 
Pioglitazone is a new antidiabetic drug, and only limited information was available 
to estimate its potential for drug-drug interactions when it came on the market at 
the start of this thesis. Although the consumption of pioglitazone is still limited, 
e.g. in Finland, 0.58 defi ned daily doses (DDD)/1000 inhabitants compared with 
46 DDD/1000 inhabitants for all oral antidiabetic drugs, its use is increasing (National 
Agency for Medicines, drug consumption statistics 2006). From the perspective of 
drug safety, we consider it important to investigate potential interactions of this 
new drug before its wide clinical use. 
Pioglitazone can cause fl uid retention and peripheral oedema, which can lead to or 
exacerbate heart failure and pulmonary oedema (Waugh et al. 2006). Th e precise 
mechanism of this adverse reaction is not known, but it appears to be a dose-related 
class eff ect of the thiazolidinediones (Macfarlane and Fisher 2006). Gemfi brozil raised 
the mean AUC of pioglitazone over 3-fold, and a 6.5-fold increase was observed in one 
subject. It is thus possible that concomitant use of gemfi brozil with pioglitazone may 
increase the risk of this concentration-dependent adverse eff ect of pioglitazone. 
Th e blood glucose lowering eff ect of pioglitazone develops gradually over a period 
of weeks and is dose-dependent (Aronoff  et al. 2000). Th e AUC values of the active 
metabolites of pioglitazone were not reduced by gemfi brozil. Th us, the net eff ect of 
gemfi brozil is likely an increase in the effi  cacy of pioglitazone, although this was not 
investigated in the present single-dose study.
Rifampicin considerably decreased the plasma concentrations of total active 
compounds of pioglitazone, and concomitant use of rifampicin with pioglitazone 
may decrease the effi  cacy of pioglitazone. Other CYP2C8 enzyme inhibitors or 
inducers probably also could alter the plasma concentrations of pioglitazone. It is 
thus advisable to monitor blood glucose concentrations when starting treatment with 
gemfi brozil or rifampicin (or other drugs aff ecting CYP2C8 activity) and to adjust 
pioglitazone dosage as necessary. Furthermore, reducing the dosage of pioglitazone 
when rifampicin treatment is discontinued is important. However, further long-
term studies in patients with type 2 diabetes receiving pioglitazone are needed to 
determine the clinical signifi cance of these interactions.
DISCUSSION
Jaakkola_Tiina_vaitos.indd   56 17.7.2007   21:12:07
57
CONCLUSIONS
Th e following conclusions can be drawn on the basis of the results of Studies I-V:
1. Pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by 
CYP3A4 in vitro. CYP2C9 appears to be insignifi cant in the total elimination of 
pioglitazone. Montelukast, zafi rlukast, gemfi brozil and trimethoprim markedly 
inhibit pioglitazone metabolism in vitro. 
2. Gemfi brozil elevates the plasma concentrations of pioglitazone, most likely 
by inhibiting its CYP2C8-mediated metabolism. Concomitant use of gemfi brozil 
with pioglitazone may increase the effi  cacy and concentration-related adverse 
eff ects of pioglitazone. CYP3A4 appears to be of minor importance in pioglitazone 
metabolism in vivo.
3. Montelukast and zafi rlukast do not increase the plasma concentrations of 
pioglitazone, indicating that their inhibitory eff ect on CYP2C8 is negligible 
in vivo, despite their strong inhibitory eff ect on CYP2C8 in vitro.
4. Rifampicin caused a substantial decrease in the plasma concentrations of 
pioglitazone, probably by induction of CYP2C8. Concomitant use of rifampicin 
with pioglitazone may decrease the effi  cacy of pioglitazone.
5. Pioglitazone does not increase the plasma concentrations of repaglinide, 
indicating that the inhibitory eff ect of pioglitazone on CYP2C8 and CYP3A4 is 
very weak in vivo. Th e synergistic eff ect of pioglitazone and repaglinide seen in 
patients with type 2 diabetes is unlikely to be caused by pharmacokinetic 
interaction.
6. Th ese fi ndings highlight the importance of in vivo interaction studies and the 
incorporation of relevant pharmacokinetic properties of potentially interacting 
drugs, including their plasma protein binding, into in vitro – in vivo interaction 
predictions.
CONCLUSIONS
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